The QualityStocks Daily Friday, October 23rd, 2020

Today's Top 3 Investment Newsletters

QualityStocks (TWOH) +76.09%

InvestorPlace (SCKT) +74.66%

MarketClub Analysis (MRIN) +62.74%

The QualityStocks Daily Stock List

American Battery Metals Corporation (ABML)

OTC Markets, Corporate Information, Stockwatch, Real Investment Advice, Proactive Investors, Investor Place, TipRanks, Newsfilecorp, WasteAdvantageMag, Penny Stock Hub, Mining Capital, Investors Hangout, Mining Stock Education, Investing News, QuoteMedia, Baystreet.ca. Digital Journal, Business Insider, Stockhouse, Investment Pitch, YCharts, Mining Journal, Investing.com, Wallet Investor, Simply Wall St, Big News Network and Mining.com reported previously on American Battery Metals Corporation (ABML), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

American Battery Metals Corporation is a premier battery metal exploration and development company. Its focus is on its Railroad Valley battery metal project in the State of Nevada with the goal of becoming a major domestic supplier of battery metals to the growing electric vehicles (EV) and battery storage markets in the USA. The Company formerly went by the name Oroplata Resources, Inc. It changed its name to American Battery Metals Corporation in May of 2019. Incorporated in 2011, American Battery Metals is headquartered in Incline Village, Nevada. The Company lists on the OTC Markets’ OTCQB.

American Battery Metals, through its subsidiaries, engages in the exploration and development of lithium properties. It announced in July of 2019 that results of its first geophysical exploration program demonstrate that a large and undefined reservoir exists on its property in Railroad Valley, Nevada.

The geophysical Magnetotelluric (MT) Survey was conducted over a square mile area by Zonge International of Reno, Nevada. Zonge has wide-ranging experience in geophysical data acquisition and target identification on Lithium Exploration Projects. The results of the geophysical survey indicate two large conductive zones located within the project area. "Conductive Zones" could indicate the presence of Lithium concentration in shallow clay deposits and in deeper Brine deposits. One of these conductive zones was previously drill tested to a depth of 3,000 feet.

Currently, American Battery Metals has mining claims on 26,000 acres in the area called the Western Nevada Basin, in Railroad Valley in Nye County, Nevada (WNB Claim). In the second half of 2017, the Company engaged experts to evaluate the area and the WNB Claim to target on-site exploration efforts. It ascertained that 260 claims of the WNB Claim were appropriate for its planned exploration that commenced in April of 2019.

The Company recently announced its intention to change its corporate name to American Battery Technology Company. This is to better reflect its main focus and mission. Over the past number of months, it has readied and positioned itself for its planned lithium-ion battery metals recycling plant in Nevada, with many new hires, including several from Tesla.

This past August, American Battery Metals announced that it finalized the initial equipment orders for its first lithium-ion battery metals recycling plant. Its internally developed lithium-ion battery recycling system comprises two distinct phases of processing operations. The first phase enables the feeding of battery end-of-life materials and battery manufacturing waste, and the quick disassembly and separation of these feedstock materials into intermediate products of value.

At first, these intermediate products will sell directly to the secondary processing markets to enable profitable operations. Nonetheless, subsequently further value add operations in the second phase of the Company’s process will be implemented to further boost margins and these intermediate products will instead be upgraded to battery grade metal feedstocks to sell back into the high energy density cathode supply chain.

Yesterday, American Battery Metals announced the appointment of Mr. David Corsaut as Chief Financial Officer (CFO). Mr. Corsaut is a veteran leader of companies in the technology, manufacturing, logistics, finance, as well as real estate sectors. He was instrumental in providing the capital formation for the companies he managed. Most recently, Mr. Corsaut led Coolfire Solutions as Chief Operating Officer (COO).

American Battery Metals Corporation (ABML), closed Friday's trading session at $0.166, off by 0.895522%, on 1,783,885 volume with 274 trades. The average volume for the last 3 months is 3,817,631 and the stock's 52-week low/high is $0.02438/$0.214000001.

American International Holdings Corp. (AMIH)

Stocks to Buy, Equities.com, Wolf Street, Street Insider, Research Pool, FX Empire, Dividend.com, Simply Wall St, Dividend Investor, TeleTrader, Current Charts, GlobeNewswire, Morningstar, Telecom Reseller, Stockopedia, Nasdaq, Marketing TechWire, Stockhouse, Wallet Investor, last10k, CEO.ca, Seeking Alpha, TipRanks, GuruFocus, Nasdaq, OTC Markets, docoh, Investors Hub, Trading View, Market Screener and MarketWatch reported beforehand on American International Holdings Corp. (AMIH), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

American International Holdings Corp. is a diversified holding company listed on the OTC Markets. Its commitment is to acquiring, managing, and operating health, wellness, beauty, and lifestyle companies, businesses and/or brands located in the U.S. and internationally. The Company looks for opportunities to acquire and grow businesses that have strong brand values and that can produce long-term sustainable free cash flow and attractive returns to maximize value for American International and its stakeholders. Incorporated in 1986, American International Holdings has its corporate headquarters in Addison, Texas.

American International owns and operates a medical spa under the Novopelle brand name in McKinney, Texas. It also has its wholly-owned subsidiary, Capitol City Solutions USA, Inc. (CCS). CCS was formed to act as a general contracting and construction company centered on the remodeling, general construction, and interior finish of American International’s Novopelle branded med spa locations, as well as to market to other commercial real estate projects within the United States.

American International Holdings’ wholly-owned subsidiary, Novopelle Waterway, Inc. officially opened the doors to its Novopelle Med Spa located at the award-winning Woodlands Waterway in The Woodlands, Texas, on Tuesday, February 25, 2020. This is the second Novopelle Med Spa location to be established and operated by the Company.

American International Holdings’ dedication is also to operating and managing an online platform providing customers with access to life and career coaches via LifeGuru, Inc. (www.LifeGuru.me, which is now in development). Moreover, its dedication is to operating and managing an online telemedicine platform connecting customers to Board certified physicians and licensed mental and behavioral health counselors via ZipDoctor, Inc. (www.ZipDoctor.co).

In September, American International Holdings announced that it has retained the services of Captify Consulting to lead, support, as well as champion the ZipDoctor’s digital marketing and social media advertising efforts as it relates to its recently launched subscription based online telemedicine platform, located at www.ZipDoctor.co. ZipDoctor’s online telemedicine platform is available to customers throughout the U.S. It offers bilingual coverage (English and Spanish), with virtual visits taking place either through the phone or via a secured video chat platform. Captify specializes in helping B2C (Business 2 Consumer) companies, eCommerce Brands, and entrepreneurs scale and boost their revenue with highly-targeted, consistently-converting digital advertisement campaigns.

American International Holdings Corp. (AMIH), closed Friday's trading session at $0.1419, off by 2.1379%, on 15,046 volume with 10 trades. The average volume for the last 3 months is 41,033 and the stock's 52-week low/high is $0.082099996/$2.40000009.

AMMO, Inc. (POWW)

NetworkNewsWire, Business Insider, OTC Dynamics, last10k, Infront Analytics, StockInvest.us, TipRanks, YCharts, Barchart, Dividend.com, EIN News, Investors Hangout, Stockopedia, Wallmine, Financial Buzz, Tiingo, Market Screener, Trading View, MarketWatch, TeleTrader, Dividend Investor, Stockhouse, 4-Traders, InvestorsHub, Simply Wall St, Equity Clock, Seeking Alpha, Macroaxis, Savvy Trader, GlobeNewswire, GuruFocus, Morningstar, Wallet Investor, Investor Place and Stockwatch reported beforehand on AMMO, Inc. (POWW), and today we report on the Company, here at the QualityStocks Daily Newsletter.

AMMO, Inc. is a technology leader and premier American ammunitions manufacturer. The Company designs and manufactures products for an array of aptitudes. These include law enforcement, military, hunting, sport shooting, and self-defence. The Company operates a munitions manufacturing facility in Payson, Arizona. It also operates a brass casings manufacturing facility in Manitowoc, Wisconsin. Established in 2016, AMMO is based in Scottsdale, Arizona. The Company’s shares trade on the OTC Markets Group’s OTCQB.

The ammunition AMMO makes performs like high end custom hand loaded ammunition. The Company works to be the leading innovator of center-fire ammunition for military, law enforcement, and civilians. Every load is developed for a specific purpose. The focus is on consistency, accuracy, and, in some cases, felt recoil. Each round is designed, manufactured, inspected, and packaged to bring a first-rate shooting experience to AMMO’s end consumer. In addition, the Company’s HyperClean technology enables its customers to shoot more and clean less.

AMMO promotes branded munitions. These include its patented STREAK™ Visual Ammunition, the Jesse James line of munitions and accessories, /stelTH/ subsonic munitions, O.W.L. Technologies®, TAC-PTM Tactical Precision Defense munitions, and OPS (One Precise Shot). OPS is a lead-free frangible tactical line of munitions for self-defence.

AMMO has its patented Hard Armor Piercing Incendiary (HAPI) and Armor Piercing (AP) ammunition manufacturing line. It is presently manufacturing best-in-class 308 (7.62x51mm) and .338 ammunition in HAPI and AP variants for use by its U.S. and overseas military and law enforcement partners. AMMO’s work in industrializing the manufacturing of its AP and HAPI ammunition was purposely deployed to serve the growing global military and law enforcement ammunition market.

Earlier this week, AMMO announced it has continued to receive consistent order flow with its backlog of booked orders in excess of $100 million. In an effort to boost production and fulfillment capacity, the Company recently invested in roughly $2.5 million of new equipment.

AMMO plans to attend the 2021 SHOT Show in Las Vegas, Nevada. It is being held January 19-22, 2021. AMMO will be featuring a new booth at the show. The Company will provide complete details on its attendance as the date of the event gets closer.

Yesterday, AMMO announced it has expanded its IP portfolio as a result of the U.S. Patent and Trademark Office (USPTO)’s issuance of Patent No. 10,801,821 recognizing AMMO’s development of a protectable and innovative process to mass-produce luminescent projectiles, and also the luminescent projectiles manufactured as a result of the protected process. This method and process patent further enhances the value derived from AMMO’s patented STREAK™ Visual Ammunition (U.S. Patent No. 8,402,896 B1).

AMMO, Inc. (POWW), closed Friday's trading session at $2.51, up 1.2097%, on 126,299 volume with 267 trades. The average volume for the last 3 months is 108,869 and the stock's 52-week low/high is $0.959999978/$3.06999993.

Ekso Bionics Holdings, Inc. (EKSO)

Stocktwits, Zacks, Stock Consultant, OTC Markets, Whale Wisdom, Finviz, Morningstar, Market Screener, Webull, Simply Wall St, GuruFocus, Stock of the Week, Business Insider, Fintel, Trade Ideas, StockNews, YCharts, Investing.com, InvestorsHub, MarketBeat, Nasdaq, GlobeNewswire, ETF.com, The Street, TMX.com, Seeking Alpha, Stockhouse, Barchart, Annual Reports, and MarketWatch reported earlier on Ekso Bionics Holdings, Inc. (EKSO), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

NasdaqGS-listed, Ekso Bionics Holdings, Inc. is an industry leader in exoskeleton technology for medical and industrial use. Fundamentally, the Company creates wearable technology to augment human potential. It is the leading exoskeleton company to provide technologies, which help those with paralysis to stand up and walk, enhance worker capabilities worldwide, and provide research for the advancement of R&D projects intended to benefit U.S. defense capabilities. Established in 2005, Ekso Bionics Holdings has its corporate headquarters in Richmond, California.

The Company is a foremost developer of exoskeleton solutions that amplify human potential through supporting or enhancing strength, endurance, and mobility across medical and industrial applications. Ekso’s focus is to build upon its industry-leading expertise to design some of the most innovative, pioneering wearable robots available on the market today.

Ekso Bionics develops disruptive clinical robotics to tackle loss of mobility and cognition. The Company has helped thousands of patients take greater than 130 million Ekso-aided steps. Moreover, Ekso has lowered the number of workers injured on the job with Eksoworks. It has EVO, which is the next evolution of EksoVest. EVO is an upper-body exoskeleton designed to boost productivity and lessen fatigue, with the aim of eliminating work-related injuries to the neck, shoulder, and back.

Ekso Bionics also has its EksoZeroG. This is a robotic aerial system that supports heavy power tools on aerial work platforms so workers have more endurance, accuracy, as well as safety. Furthermore, the Company has its EksoNR. This is its lower-body clinical rehabilitation device. It was the first exoskeleton Food and Drug Administration (FDA)-cleared for stroke and spinal cord injury, and the only exoskeleton FDA-cleared for acquired brain injury. Ekso has expanded into upper-body rehabilitation with the new EksoUE.

Yesterday, Ekso Bionics Holdings announced that it will release financial and business results for Q3 2020 after the close of trading on Thursday, October 29, 2020. Company Management will host a conference call starting at 1:30 p.m. PT / 4:30 p.m. ET to discuss the financial results and recent business developments.

Ekso Bionics Holdings, Inc. (EKSO), closed Friday's trading session at $4.76, up 6.7265%, on 64,921 volume with 547 trades. The average volume for the last 3 months is 146,743 and the stock's 52-week low/high is $2.25/$11.7749996.

Rasna Therapeutics, Inc. (RASP)

NetworkNewsWire, BioSpace, OTC Markets, Morningstar, Businesswire, Market Screener, Seeking Alpha, InvestorsHub, Dividend.com, Market Exclusive, Business Insider, Stockhouse, last10k, Morningstar, Wallet Investor, Fintel, TipRanks, MarketWatch, FX Empire, Dividend Investor, Simply Wall St, docoh, Stockopedia, GuruFocus, CSI Market, Barchart, The Globe and Mail and Nasdaq reported earlier on Rasna Therapeutics, Inc. (RASP), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Rasna Therapeutics, Inc. is developing therapies for Acute Myeloid Leukemia (AML) and other life-threatening leukemias. Its primary indication is AML, which may be fatal within weeks to months, has a 5-year survival rate of only approximately 25 percent, and very poor prospects for long-term survival of patients. Rasna has a balanced portfolio targeting NPM1-mutated AML by way of direct and indirect disease-modifying approaches. In addition, it is exploiting inhibition of lysine specific demethylase-1 (LSD1), an enzyme involved in epigenetic control, as a promising and novel approach against AML.

The Company is headquartered in New York, New York. Its research and development (R&D) team is located at its laboratory facilities in Doylestown, Pennsylvania. Founded in 2013, Rasna Therapeutics’ shares trade on the OTC Markets Group’s OTCQB. The Company has lead programmes in the clinic, with each targeting a key regulator of cancer. Its R&D pipeline includes RASP-101 - Formulated RASP-101. The original drug dactinomycin (Cosmegen®) has shown complete remission in 40 percent of AML patients (N=10).

In addition, the Company’s pipeline includes RASP-201 - LSD1 Lysine-Specific - Demethylase 1 (Novel inhibitors of LSD-1, a pathway that blocks differentiation and confers a poor prognosis in AML). LSD-1 has already been identified as an important druggable target.

Moreover, Rasna Therapeutics pipeline also includes RASP-301 NPM1 – Nucleophosmin. This is a first in class NCE for NPM1, presently at the pre-clinical stage, this orally available small molecule has the potential to treat refractory AML with lessened toxicity.

Last week, Rasna Therapeutics announced that Mr. Willy Simon has been appointed as the Chairman of Rasna Therapeutics. He replaces Alessandro Padova, who resigned for personal reasons. Mr. Simon is a banker and worked at Kredietbank N.V. and Citibank London before serving as an Executive Member of the Board of Generale Bank NL from 1997 to 1999 and as the Chief Executive of Fortis Investment Management from 1999 to 2002.

Rasna Therapeutics, Inc. (RASP), closed Friday's trading session at $0.09, even for the day, on 30,000 volume. The average volume for the last 3 months is 56,312 and the stock's 52-week low/high is $0.0103/$0.330000013.

Target Hospitality Corp. (TH)

Stocktwits, Stockzoa, Analyst Ratings, Whale Wisdom, Market Chameleon, Webull, S&P Global Market Intelligence, TipRanks, Simply Wall St, TradingView, Investing.com, Stocks.TradingCharts, Investors Observer, Business Wire, Dividend.com, ADVFN.com, Morningstar, Barchart, Directors Talk Interviews, Seeking Alpha, Wallet Investor, Nasdaq, GuruFocus, last10k, YCharts and ETF.com reported earlier on Target Hospitality Corp. (TH), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Target Hospitality Corp. is the largest provider of vertically-integrated specialty hospitality accommodations with first-rate catering and value-added hospitality services in the United States. The Company builds, owns, and also operates customized housing communities for a range of end users. Target Hospitality provides a complete set of cost-effective hospitality solutions. These include culinary, catering, concierge, laundry, security services, and recreational facilities. Target Hospitality is based in The Woodlands, Texas. The Company lists on the Nasdaq Global Select Market.

Target Hospitality is a worldwide provider of turnkey accommodations and hospitality solutions. It coordinates every component of building and operating a workforce lodging community. The Company custom builds workforce housing accommodations to fulfill any need or specification. This is from basketball courts to BBQ pits, catering to housekeeping services, 24-hour travel professionals to on-site transportation management.

The Company chiefly serves the energy and government sectors. It handles everything and outsources nothing. The design of its increasing network of 25 communities with greater than 13,000 rooms is to maximize workforce productivity and satisfaction. Target Hospitality has its Lodge Network. Its existing lodges provide value to companies and accommodations. Target provides a totally operating Housing Community that is already up and running. It offers turnkey accommodations and hospitality solutions.

The Company’s oil field hospitality and lodge management services include Catering; Accounting; Security, and Communications. Furthwermore, Oil field hospitality and lodge management services include Maintenance/Housekeeping; Laundry; HSE, as well as Quality Control/Assurance.

Regarding Temporary Workforce Housing, Target Hospitality provides temporary oil field housing, temporary apartments in an Olympic village, or housing for disaster relief workers. It customizes to a client’s requirements and preferences. Moreover, it provides short-term, long-term, affordable, and comfortable turnkey accommodations and hospitality solutions.

Target Hospitality has been awarded the GSA Professional Services Schedule (PSS) contract enabling it to provide logistics solutions to government agencies. The Company provides a wide array of housing, deployment, operations, and management services through its GSA Professional Services Schedule agreement.

Target Hospitality will release its Q3 2020 financial results before the market opens on Monday, November 9, 2020. It has scheduled a conference call for Monday, November 9, 2020 at 9:00 am Eastern Time (8:00 am Central Time) to discuss the results.

Target Hospitality said it continued to see steady improvements in its operating metrics during Q3, with the pace of the improvements surpassing expectations. Demand for its Permian Basin accommodations continues to improve, as customer activity has steadily risen from lows experienced during Q2.

The Company anticipates these trends will continue, at a moderated pace, through the rest of 2020 and into 2021. Also, it has made progress in renewal discussions for its government services contract. It anticipates a positive outcome for a contract renewal, at attractive economics, by the end of this year.

Target Hospitality Corp. (TH), closed Friday's trading session at $1.17, off by 0.847458%, on 95,303 volume with 403 trades. The average volume for the last 3 months is 145,184 and the stock's 52-week low/high is $1.14999997/$5.86999988.

Zinc8 Energy Solutions, Inc. (MGXRF)

Street Insider, North American Clean Energy, Rockstone Research, Junior Mining Network, Market Screener, Financial Buzz, Investor Place, GuruFocus, TradingView, Finscreener, Morningstar, FX Empire, Equities.com, Proactive Investors, Nasdaq, Resourcelips.com, The Globe and Mail, ADVFN.com, Dividend Investor, Wallet Investor, Seeking Alpha, MarketWatch, Stockhouse, InvestorX, TMX.com, and Simply Wall St reported earlier on Zinc8 Energy Solutions, Inc. (MGXRF), and we also highlight the Company, here at the QualityStocks Daily Newsletter.

Zinc8 Energy Solutions, Inc. focuses on the development and commercialization of a dependable low-cost zinc-air battery. This mass storage system provides environmental and efficiency benefits. The Company previously went by the name MGX Renewables, Inc. It changed its corporate name to Zinc8 Energy Solutions in September of 2019. Incorporated in 2011, the Company has its head office in Vancouver, British Columbia. Zinc8 Energy Solutions’ shares trade on the OTC Markets.

The Company’s dedication is to redefining long-duration energy storage. It has developed unique battery technology that utilizes zinc and air as fuel. In essence, its technology resolves the intermittent and unpredictable nature of renewable energy sources such as wind and solar. It does so while totally decoupling the linkage between power and energy.

Power from the grid or renewable source is utilized to generate zinc particles in the Zinc Regenerator. Oxygen is released to the atmosphere as a by-product. The zinc particles are flowed to the Storage Tank. They are maintained in potassium hydroxide (KOH) electrolyte until needed. Whenever power is required, the zinc particles are delivered to the Power Stack, recombining them with oxygen to produce electricity. The zinc oxide (ZnO) by-product is returned to the storage tank for later regeneration.

Recently, Zinc8 Energy Solutions announced that it was chosen as a winner of the New York City (NYC) Department of Buildings Carbon Neutrality Innovation Challenge. Four companies, including Zinc8 Energy Solutions, were chosen with the aim of increasing energy efficiency in NYC. The winners of the Challenge will be supported for inclusion in the 2020 NYC Building Code. Zinc8 Energy Solutions’ Patented Zinc-air Energy Storage Solution was the only energy storage solution selected as a winner.

This week, Zinc8 Energy Solutions announced that it signed an agreement in principle with Australian Engineering firm SmartConsult (The Wyer Company Pty Ltd, trading as SmartConsult). The parties have agreed to explore Joint-Venture (JV) projects regarding the deployment of Zinc8's patented Zinc-Air Energy Storage System.

This Agreement centers on deploying Zinc8's Zinc-Air Energy Storage System at aquatic centres, remote mines, and behind-the-meter applications using SmartConsult's wide-ranging knowledge, contacts in and relations with a wide variety of energy users, energy systems suppliers across Australia, and a pipeline of customers.

Zinc8 Energy Solutions, Inc. (MGXRF), closed Friday's trading session at $0.17787, off by 6.3842%, on 96,478 volume with 23 trades. The average volume for the last 3 months is 86,021 and the stock's 52-week low/high is $0.057999998/$0.400000005.

Two Hands Corporation (TWOH)

OTC.Watch, The Hot Penny Stocks, CSI Market, YCharts, Barchart, InvestorsHub, Seeking Alpha, Global Banking and Finance, Business Insider, Investing.com, Morningstar, Stockwatch, OTC Markets, Wallet Investor, OTC Dynamics, StockReads, Ask Finny, Market Wire News, Market Screener, Trade Ideas, TradingView, Simply Wall St, Stockhouse, last10k, and Accesswire reported beforehand on Two Hands Corporation (TWOH), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

Two Hands Corporation is a foremost custom application development company. Its concentration is on creating a complete co-parenting solution, delivering tools that enable co-parents to better collaborate about parental responsibilities, in a clear and positive way. The Company previously went by the name Innovative Product Opportunities, Inc. It changed its name to Two Hands Corporation in September of 2016. Established in 2009, Two Hands Corporation is headquartered in Toronto, Ontario.

The Company’s "Two Hands" web application launched in July of 2018. Two Hands’ ultimate objective is to improve the lives of families affected by divorce. Two Hands states that "Two Hands" is an ideal solution that will lessen the stress and worries of co-parenting.

Regarding the Company’s other offerings, Two Hands’ Gone App enables one to send encrypted text messages right from their phone, combining military-grade security, confidentiality, and privacy – with premier convenience, right at their fingertips. All text messages are asymmetrically encrypted. It is safe, with keys that only the rightful user owns. Gone App features Message Auto-Deletion after being read; no preview, one must click to view the message; and Screen Capture is disabled.

In addition, Two Hands Corp Lab is an organic hemp based CBD (cannabidiol) cultivator located in Colombia. Two Hands Corp Lab is vertically integrated, producing from seed to wholesaler. It will distribute its high grade hemp based oil mainly through Latin America and Australia. Also, it will expand its reach once countries allow for importation.

Moreover, Two Hands Corporation has diversified. This is to meet new demand for online delivery because of the present Covid-19 Pandemic. In May, Two Hands announced it was ready to launch the GoCart brand of grocery delivery applications in early June. Its GoCart Online Grocery Delivery set of applications will be rolled out in stages to meet the increasing demand for online grocery delivery.

Recently, Two Hands Corporation announced that the on-demand marketplace for groceries has officially launched the mobile version of its' online grocery delivery service. It is now available on Android and iOS. This app is integrated with Google and Apple Pay for safe and secure transactions.

GOCART.CITY offers farm fresh, artisanal, and specialty grocery selections, delivered right to one’s doors. Customers can easily select their choice of fresh produce, quality cut fruits and vegetables, and a broad array of day-to-day grocery items.

Two Hands Corporation (TWOH), closed Friday's trading session at $0.00405, up 76.087%, on 52,643,755 volume with 415 trades. The average volume for the last 3 months is 9,534,944 and the stock's 52-week low/high is $0.0024/$1.79999995.

Recruiter.com Group, Inc. (RCRT)

Zacks, Wallet Investor, Penny Stock Hub, Last10k, TradingView, OTC Markets, GlobeNewswire, Nasdaq, Investors Hangout, Stockopedia, Dividend Investor, GuruFocus, InvestorsHub, Dividend.com, Stockhouse, MacroTrends, Investor Ideas, Market Wire News, and TipRanks reported earlier on Recruiter.com Group, Inc. (RCRT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Recruiter.com Group, Inc. is a leading platform connecting recruiters and employers. An expert network for recruiters, the Company pairs enterprises with an extensive network of recruiters and powerful AI (Artificial Intelligence) matching tools to foster the hiring of premier talent faster and smarter. Recruiter.com provides recruiters SHRM certified recruitment training and independent earning opportunity. It provides enterprise and mid-market employers recruiting services designed to scale across a varied range of skills and industries.

Recruiter.com Group is headquartered in Houston, Texas. The Company also has additional offices in Bristol, Connecticut, and Ebene, Mauritius. Recruiter.com Group lists on the OTC Markets Group’s OTCQB.

The Company has strategic partnerships in manifold areas of the recruitment process. These include AI candidate matching software, applicant tracking systems, job sites, resume writing and career services, recruitment and career content providers, and recruitment service and outsourcing firms.

The design of Recruiter.com’s business is to accelerate recruiting and hiring success by way of technology adoption. The Company’s chief product and service is its cloud-based “Job Market” software platform for professional hiring. The Job Market software facilitates connections to a nationwide network of professional recruiters.

Furthermore, the Job Market software is augmented by proprietary AI technologies that draw from talent communities of millions of people. Recruiter.com provides employers a flexible, performance-based hiring model for permanent and contract talent.

Recruiter.com Group has a strategic partnership agreement with Censia, Inc. Censia is the operator of a worldwide talent intelligence platform with half a billion of the world’s professionals, indexed and analyzed through AI. This partnership with Censia enables Recruiter.com’s network of independent recruiters and internal Talent Delivery team access to Censia on a performance basis.

This past February, Recruiter.com announced the launch of its Recruiters on Demand solution offering. The Recruiters on Demand program is a flexible, monthly solution to easily add recruiters to a team without the commitment of hiring full-time staff recruiters. Employers can use the program to scale their internal talent acquisition teams on an as-required basis through hiring independent recruiters from Recruiter.com. Recruiters on Demand provides Human Resources departments and recruitment teams the opportunity to hire recruiters either virtually or on-site on location.

Recently, Recruiter.com announced a partnership with DVBE Connect to build a curated on-demand team of veteran recruiters. DVBE is an award-winning, disabled veteran-owned recruiting and staffing enterprise. Recruiter.com enables any employer to easily add recruiters to their talent acquisition team to get them through a period of fast-growth and hiring, with simple, flat monthly pricing and no success fees.

Recruiter.com Group, Inc. (RCRT), closed Friday's trading session at $1.94, up 37.5887%, on 16,674 volume with 38 trades. The average volume for the last 3 months is 2,930 and the stock's 52-week low/high is $0.560000002/$4.99989986.

Marker Therapeutics, Inc. (MRKR)

Market Chameleon, TipRanks, BioSpace, BioPharmCatalyst, iwatchmarkets, Investor Village, YCharts, Investing.com, Barchart, MacroTrends, TMXmoney, Stockhouse, InvestorsHub, Simply Wall St, Market Screener, Fosters Research, Trade Ideas, Finviz, Zacks, Equity Clock, GuruFocus, Finbox, Street Insider, Ceo.ca, ChartMill, Proactive Investors, Analyst Ratings, PR Newswire, Nasdaq, MarketWatch, Seeking Alpha, Morningstar, Stocktwits, and Dividend Investor reported earlier on Marker Therapeutics, Inc. (MRKR), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

A clinical-stage immuno-oncology company, Marker Therapeutics, Inc. specializes in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. The Company is also developing unique peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, and PolyStart™, a proprietary nucleic acid-based antigen expression technology designed to improve the ability of the immune system to recognize and destroy diseased cells. Marker Therapeutics lists on the NasdaqGM. The Company is based in Houston, Texas.

Marker Therapeutics developed its lead product candidates from its MultiTAA T cell technology that is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens (TAAs), which are tumor targets, and then kill tumor cells expressing those targets. The design of these T cells are to recognize numerous tumor targets to produce broad-spectrum anti-tumor activity.

Marker is advancing two MultiTAA T cell pipelines. One is its autologous T cells for the treatment of lymphoma, multiple myeloma, and selected solid tumors. The other is its allogeneic T cells for the treatment of acute myeloid leukemia, or AML, and acute lymphoblastic leukemia, or ALL. Because the Company does not genetically engineer its MultiTAA therapies, it believes that its product candidates are easier and less costly to manufacture, with reduced toxicities, than present engineered CAR-T and T cell receptor-based therapies, and may provide patients with meaningful clinical benefit.

In June, Marker Therapeutics announced that the United States Adopted Names (USAN) Council approved "zelenoleucel" as the nonproprietary (generic) name for MT-401, a multi-tumor-associated antigen (MultiTAA)-specific T cell product candidate for the treatment of patients with acute myeloid leukemia (AML) following allogeneic stem cell transplant in adjuvant and active disease settings.

Mr. Peter L. Hoang, President & Chief Executive Officer of Marker Therapeutics, said, "The USAN approval of zelenoleucel as the generic name for MT-401 is another step forward for continued advancement of our therapy. MT-401, which received Orphan Drug designation from the U.S. FDA in April, has shown clinical benefit in patients with acute myeloid leukemia post stem cell transplant in an investigator-sponsored trial. We are excited about the continued clinical development of zelenoleucel and look forward to initiating our Company-sponsored Phase 2 study in patients with AML following transplant."

Recently, Marker Therapeutics announced that it executed a lease agreement to establish a cGMP manufacturing facility in Houston, Texas, in an area near the George Bush Intercontinental Airport. The facility will allow production according to U.S. Food and Drug Administration (FDA) guidelines. The design of the facility is to be scalable using modular processes. The expectation is that the facility will be completed by year-end and operational in 2021.

Marker Therapeutics, Inc. (MRKR), closed Friday's trading session at $1.62, even for the day, on 46,891 volume with 200 trades. The average volume for the last 3 months is 207,709 and the stock's 52-week low/high is $1.33000004/$4.34000015.

Verus International, Inc. (VRUS)

Transparent Traders, Last10k, Stockopedia, Insider Tracking, Market Screener, Stockwatch, InvestorsHangout, Market Wire News, TradingView, Stockhouse, News Planets, InvestorsHub, GlobeNewswire, and Simply Wall St reported earlier on Verus International, Inc. (VRUS), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Verus International, Inc. operates a global food subsidiary (Verus Foods) that sells branded consumer products to customers around the world. The Company has developed premier food products sourced in the U.S. and exported them internationally. Verus works very closely with its local and international suppliers to deliver the finest food products at reasonable prices.

The Company lists on the OTC Markets Group’s OTCQB. Verus International has its corporate headquarters in Gaithersburg, Maryland. It was previously known as RealBiz Media Group, Inc. The Company changed its name to Verus International, Inc. in October of 2018.

Verus centers on the regional sensitivities and dietary requirements in the markets that it exports to. The Company’s dedication is to quality control and food safety. It closely monitors every step of the process meticulously. This is to ensure its strict food quality and production guidelines are met. This is from sourcing, production, packing, to shipping.

Verus International’s products include Condiments, Meat & Poultry, Ice Creams, Vegetables/French Fries, Commodities, and Candy. Commodities include Pulses & Legumes, Grains, as well as Rice. Verus Foods distributes and delivers its food products via an array of channels. This includes wholesale, van sales, retail and HORECA (Hotel/Restaurant/Café).

Recently, Verus International announced that it signed a revolving line of credit (LOC) with The Columbia Bank, N.A. (a Fulton Financial Corporation affiliate). The revolving credit line is immediately available for eligible foreign trade financing.

Verus International can immediately start to deploy this source of funds for new business. Based on current average inventory turns, Verus believes that the LOC can generate from $7M to $10M in annual revenue (depending upon the product mix). In addition to this agreement, the Company is also exploring other vendor and trade relationships, which can increase its growth trajectory through favorable terms that help minimize the financing for each shipment.

Verus International, Inc. (VRUS), closed Friday's trading session at $0.0011, up 37.50%, on 106,848,166 volume with 233 trades. The average volume for the last 3 months is 189,665,407 and the stock's 52-week low/high is $0.000699999/$0.0296.

Wealth Minerals Ltd. (WMLLF)

NetworkNewsWire, StreetWise Reports, Zacks, Stocks.TradingCharts, Investing News, GlobeNewswire, Stockhouse, Junior Mining Network, and Proactive Investors reported earlier on Wealth Minerals Ltd. (WMLLF), and today we report on the Company, here at the QualityStocks Daily Newsletter.

A junior mineral resource exploration company, Wealth Minerals Ltd. engages in the acquisition, exploration, and development of mineral properties in Canada, Mexico, Peru, and Chile. Its primary emphasis is the acquisition and development of lithium projects in South America. To date, Wealth Minerals has positioned itself to develop the Atacama Project alongside existing producers in the prolific Atacama region, where the Company has a considerable licenses package. Wealth Minerals is headquartered in Vancouver, British Columbia. The Company lists on the OTC Markets’ OTCQX.

Wealth Minerals is empowering the Green Energy Storage industry and the Electric Vehicle (EV) market. The Company is doing so with its world-class lithium projects in Chile. Regarding the Atacama Salar in Chile, Wealth Minerals has a large land position in the lithium industry’s leading salar. Its development plans are to follow upon the success of third party production facilities south of its land position in the Atacama Salar. The concessions encompass an area of roughly 46,200 hectares in the northern part of the Atacama Salar, in Region II of Chile. The Salar de Atacama is host to greater than 15 percent of the world’s known lithium reserves.

Wealth Minerals also has its Laguna Verde Project in Chile. It has an aggregate total concession size of about 6,300 hectares in Region III, northern Chile. At present, Wealth Minerals is analyzing data collected from field work studies. This includes resistivity tests that are very accurate for locating subsurface brines. The result of the analysis will give the Company drill targets that will be drilled once the seasonal factors permit so.

In addition, Wealth Minerals has its Trinity Project. Trinity consists of a number of land positions situated in close proximity to each other. Quisquiro North And South are the Trinity Project. This is where anticipated future infrastructure and management synergies can help exploit the assets’ lithium potential. Furthermore, Wealth Minerals maintains and continues to evaluate a portfolio of precious and base metal exploration-stage projects.

Recently, Wealth Minerals announced that, further to its news releases dated December 4, 2018 and April 4, 2019, its wholly-owned subsidiary, Wealth Copper Ltd. entered into a definitive share purchase agreement to acquire 100 percent of TriMetals Mining, Inc.’s (TMI) interest in and to the mineral exploitation concessions and the mineral exploration concessions (Escalones Exploration Concessions) and related assets and liabilities that consist of the Escalones copper-gold porphyry project (Escalones Project).

With the terms of the Share Purchase Agreement entered into among Wealth, Wealth Copper, TMI and Escalones Resource Corp. (a wholly-owned subsidiary of TMI), Wealth Copper will acquire a 100 percent interest in and to the Escalones Project encompassing an area of 161 km2 situated 97 km southeast of Santiago, Chile. As consideration, Wealth Copper will deliver 25,000,000 common shares in its capital to TMI, make an aggregate of $1,000,000 in cash payments to TMI, and grant to TMI a 2 percent net smelter returns (NSR) royalty on the Escalones Exploration Concessions.

Wealth Minerals Ltd. (WMLLF), closed Friday's trading session at $0.092, up 27.0718%, on 128,500 volume with 14 trades. The average volume for the last 3 months is 61,476 and the stock's 52-week low/high is $0.048149999/$0.292899996.

Truett-Hurst, Inc. (THST)

MacroTrends, Stockpools, StockTwits, Zacks, Equity Clock, PR Newswire, Street Insider, 4-Traders, MarketWatch, Simply Wall St, and Last10k reported on Truett-Hurst, Inc. (THST), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Truett-Hurst, Inc. is a holding company listed on the OTC Markets. Its sole asset is the controlling equity interest in H.D.D. LLC. H.D.D is a unique super-premium, ultra-premium and luxury wine sales, marketing and production company based in the acclaimed Dry Creek Valley of Sonoma County, California. Established in 2007, Truett-Hurst has its corporate headquarters in Healdsburg, California.

The Company produces wine from a range of varietals. These include the Pinot Noir, Chardonnay, Sauvignon Blanc, Zinfandel, Petite Sirah, Syrah, and other red blends. Truett-Hurst offers its products mainly under the VML, Truett Hurst, and Svengali brands directly through its tasting rooms, wine clubs, as well as winery Websites.

Truett Hurst Winery concentrates on ultra-premium Dry Creek Appellation wines. In 2015, the Winery was Biodynamic Certified. VML Winery focuses on Pinot Noir and Chardonnay from the Russian River Valley. It has packaging that reflects the VML commitment to natural production techniques.

The Company has its Truett Hurst Wine Club. Membership benefits include access to exclusive sales and limited release wines and up to four complementary tastings for members and their guests per visit. Membership benefits also include invitations to exclusive wine club parties and special events at the winery. In addition, Membership benefits include priority ticket purchasing opportunities for local events (Passport Weekend, Winter Wineland, Wine & Food Affair).

Recently, Truett-Hurst announced the appointment of Mr. Ross Reedy as Director of Winemaking for the Company, effective January 11, 2019. In this capacity, Mr. Reedy is responsible for all winemaking of the Truett Hurst and VML brands located in Healdsburg, California and production at the Sugarloaf Crush facility located in Santa Rosa, California. He began as a cellar assistant in 2012. Mr. Reedy studied Wine and Viticulture at Cal Poly San Luis Obispo, while at the same gaining real-world experience at a boutique winery in Paso Robles.

Truett-Hurst, Inc. (THST), closed Friday's trading session at $0.39, up 49.9423%, on 17,575 volume with 3 trades. The average volume for the last 3 months is 1,295 and the stock's 52-week low/high is $0.400200009/$1.25.

Rhino Resource Partners LP (RHNO)

Zacks, MarketWatch, Mining Connection, GlobeNewswire, Annual Reports, TopPennyStockMovers, Marketbeat, Simply Wall St, 4-Traders, Dividend Channel, Wall Street Mover, and PCG Advisory reported earlier on Rhino Resource Partners LP (RHNO), and today we report on the Company, here at the QualityStocks Daily Newsletter.   

OTCQB-listed, Rhino Resource Partners LP is a diversified energy limited partnership. It concentrates on coal and energy related assets and activities. This includes energy infrastructure investments. Rhino is a diversified energy MLP (Master Limited Partnership). It produces coal in numerous basins in the U.S. Rhino Resource Partners has its head office in Lexington, Kentucky.

The Company, through acquisitions and other coal lease transactions, has substantially increased its proven and probable coal reserves and non-reserve coal deposits. Furthermore, Rhino has successfully increased its coal production by way of internal development projects.

The Company produces metallurgical and steam coal in an array of basins across the U.S. as well as leases coal. Rhino’s strategy is to acquire coal reserves and properties with relatively long lives and that could undergo development with low risk at a reasonable cost.

Rhino produces steam coal used to produce electricity and metallurgical coal used in the steel-making process. In addition, the Company manages and leases coal properties and collects royalties from such management and leasing activities. Rhino also has oil and gas investments in the Cana Woodford region that provides added cash flows to its business. 

In Central Appalachia, approximately 72 percent of its full-year 2019 thermal and met coal production has been contracted at increased prices in comparison to 2018. Rhino’s Pennyrile, Castle Valley and Hopedale operations are considerably sold out for 2019 at prices that are above the Company’s 2018 levels. Moreover, Rhino has executed long-term contracts with different utility customers for thermal coal for 2020 at Pennyrile and Castle Valley.

Rhino Resource Partners LP (RHNO), closed Friday's trading session at $0.0525, up 31.25%, on 350 volume with 1 trade. The average volume for the last 3 months is 16,173 and the stock's 52-week low/high is $0.039999999/$1.4397.

The QualityStocks Company Corner

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) expects to have an Investigational New Drug Application (“IND”) ready for its lead drug candidate, Berubicin, by the end of 2020. An approved IND would give the biotech company, which is developing treatments for primary and metastatic cancers of the brain and central nervous system, the green light to go ahead with clinical trials. In June, CNS Pharmaceuticals signed agreements with two manufacturing entities—one in the U.S., the other in Italy—for the production of Berubicin. Also today, the company was featured in a publication from BioMedWire, examining how , when the pandemic began, many countries introduced guidelines to help curb the spread of the coronavirus. However, these recommendations are based on decades-old scientific foundations that may not reflect the current state of knowledge. Consequently, several research groups have come together to develop a better and improved model of the spread of the disease’s infectious droplets. 

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (http://nnw.fm/eDUjp).

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Friday's trading session at $1.88, up 3.2967%, on 6,532 volume with 47 trades. The average volume for the last 3 months is 95,306 and the stock's 52-week low/high is $1.25820004/$5.68989992.

Recent News

180 Life Sciences Corp.

The QualityStocks Daily Newsletter would like to spotlight 180 Life Sciences Corp..

Clinical stage biotechnology company 180 Life Sciences Corp., whose scientific teams are led by drug developers renowned for producing some of the largest-selling pharmaceuticals to ever come to market, is accelerating toward a planned Nasdaq launch under a special purpose acquisition corporation (“SPAC”) that expects to rocket its research into novel anti-inflammatory therapies toward some stellar goals.

KBL Merger Corp. IV (NASDAQ: KBLM), a special purpose acquisition corporation (SPAC), announced that, in connection with its previously detailed merger agreement with 180 Life Sciences, it consummated a bridge financing on June 29, 2020, and submitted its latest S4 filing with the SEC on August 28, 2020. It expects to close the business combination in Q4 2020. Following the merger, the company will be listed on the Nasdaq Capital Market under ticker symbol ‘ATNF’.

180 Life Sciences Corp. is a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University.

KBLM has valued 180 Life Sciences at $175 million, with the acquisition being carried out via a share swap through which each share of 180 Life Sciences will be exchanged for one share of KBLM.

Drug Development Programs

180 Life Sciences is leading the research into solving one of the world’s biggest drivers of disease – inflammation. The company is driving groundbreaking study into clinical programs, which are seeking to develop novel drugs addressing separate areas of inflammation for which there are no effective therapies.

The company’s primary platform is a novel program to treat fibrosis and inflammation using anti-TNF, with its lead program in phase 2b/3 clinical trials with first results expected in 2021. Further clinical trials are scheduled to begin by the end of 2020. The company has two additional programs that are in the preclinical stage and are showing promising results.

  • Fibrosis & Anti-TNF (Phase 2b/3 Trials): Based at the Kennedy Institute within Oxford University, the fibrosis and anti-TNF program is being led by Professor Jagdeep Nanchahal, a surgeon-scientist who has been running the phase 2 trials, and Professor Sir Marc Feldmann, a renowned immunologist and one of the pioneers of anti-TNF therapy. The program is designed to address four critical areas of inflammation:
    1. The phase 2b/3 trial evaluating the treatment of early stage Dupuytren’s disease (DD) is a fully grant-funded and enrolled study, with top line data expected to be available by Q4 2021.
    2. The phase 2b trial studying the treatment of frozen shoulder is likewise grant-funded and is scheduled to be initiated by Q3 2021.
    3. The phase 2 trial in post-operative cognitive deficit (POCD) is anticipated to commence in Q4 2021.
    4. Preclinical studies in liver fibrosis and nonalcoholic steatohepatitis (NASH) are set to begin in late 2020.
  • Inflammatory Pain (Preclinical): Directed by Professor Raphael Mechoulam at the Hebrew University in Israel, this program is focused on discovering novel compounds to treat chronic inflammatory pain.
  • A7nAChR (Preclinical): Led by Professor Lawrence Steinman and Dr. Jonathan Rothbard, 180 Life Sciences is seeking to develop a treatment for ulcerative colitis in ex-smokers by targeting the a7nAChR, a nicotine receptor in the body and a central factor in the body’s method of controlling inflammation.

Market Size for Anti-Inflammatory Medication

According to a study carried out by Allied Market Research, the anti-inflammatory therapeutics market is expected to grow to an approximate $106.1 billion annual market size in 2020, registering a CAGR of 5.9% during the period from 2015 to 2020.

Ranging from asthma treatments to targeting the causes of diseases such as arthritis, multiple sclerosis, psoriasis and inflammatory bowel disease, anti-inflammatory therapeutics have seen a sharp increase in usage, particularly given that they allow for medical responses that are more targeted and effective while possessing lesser side effects relative to conventional drugs.

Management Team

Professor Sir Marc Feldmann, Co-Chairman, is known to be a pioneer of anti-TNF therapy, which seeks to suppress the immune system by blocking the activity of TNF, a substance in the body that can cause inflammation and lead to immune-system diseases. As of today, anti-TNF therapy drugs have become the world’s largest drug class, with sales estimated at over $40 billion per annum. Feldmann has received seven international awards for biomedical innovation over the years, including the Crawford and Lasker awards, and he is a member of the Royal Society.

Professor Lawrence Steinman, Co-Chairman, is a scientific luminary, having discovered the role of integrins, which led to the creation of Natalizumab, a highlight effective treatment for multiple sclerosis and inflammatory bowel disease. Steinman is a member of the National Academy of Sciences and has received four international awards for biomedical innovation, including the Charcot Prize. Prior to joining 180 Life Sciences, Steinman founded Centocor, a pharmaceutical company that was sold to Johnson & Johnson for $4.9 billion.

Dr. James N. Woody, CEO, was instrumental in the discovery of Remicade as Chief Scientific Officer at Centocor. Previously, Woody founded Avidia and Proteolix, both of which were subsequently sold to Amgen, and he was a General Partner at Latterell Venture Partners. Boasting over 25 years of pharmaceutical research and management experience, Woody was also previously the general manager of Roche Biosciences, the former Syntex Pharmaceutical Company.

Investment Considerations

  • 180 Life Sciences boasts a world-class team responsible for developing new classes of drugs targeting multiple disease states while creating significant shareholder value.
  • The company has a large and expanding patent portfolio.
  • The risks associated with the company’s drug development efforts are mitigated through the concurrent advancement of multiple programs in different stages of development.
  • 180 Life Sciences decreases costs and expedites time to market through the use of grant funding, cost-effective international trials and recruitment of hospital-based luminaries who attract teams of excellence.

Recent News

chart

Gage Cannabis Co.

The QualityStocks Daily Newsletter would like to spotlight Gage Cannabis Co..

Bruce Linton, a pioneer of the global cannabis industry and current executive chairman of Gage Cannabis Co., has set his sights on Michigan as the next big market for the rapidly growing cannabis industry in the United States. As a leading vertically integrated operator in the industry, Gage has already made significant headway into Michigan and is well-positioned to expand its footprint in record time.

Gage Cannabis Co. is a leading vertically integrated operator in the cannabis industry led by the former CEO and Chairman of Canopy Growth Corp. (TSX: WEED) (NYSE: CGC), Bruce Linton. The company is currently focused exclusively on the Michigan market, working with the declared goal of building the fastest growing cannabis brand in the state.

One of the reasons Gage targeted Michigan as its location of choice is due to the state’s fast-growing legal cannabis market and consumption habits amongst consumers. In 2018, Michigan became the 10th state to legalize the recreational use of cannabis. In light of such favorable market dynamics, Gage opened its first medical provisioning center (dispensary) shortly after, in 2019. The company now has 13 medical or adult-use locations open or in the works, with an additional 10+ planned to open during 2021. Gage’s current portfolio features 19 Class C cultivation licenses across four cultivation assets and three processing licenses.

Current Asset and Brand Portfolio

Gage’s current brand portfolio consists of five unique product classes: flower products, edibles, hardware, concentrates and vape pens/disposables.

The company has already created relationships with a wealth of exclusive brand partners, including some of the most illustrious brands in the country. Notably, Gage’s exclusive partnership with Cookies, one of the most well-respected cannabis lifestyle brands in the United States, illustrates Gage’s operational prowess in cultivating quality flower and operating its branded retail stores. Today, Gage operates the 8 Mile Cookies location in Detroit, Michigan, which is one of the top performing dispensaries in the state despite being a medical-only dispensary.

Committed to providing only products of the highest quality, Gage uses small-batch, indoor-grown, high-quality cannabis that is hand-trimmed and hung to dry. Gage ensures that every gram of cannabis sold is consistently of the highest quality and offers a superb customer experience.

The company currently has four cultivation assets, located at Monitor Township (expansion planned), Harrison Township, Warren and Lenox Township, and it operates one processing facility located in Harrison Township, with plans to operate another two processing facilities in Monitor Township and Lenox.

Its operating dispensaries include Ferndale (adult-use), Adrian (adult-use), Lansing (adult-use), Traverse City (medical) and Detroit (Cookies establishment – medical). Additional dispensaries coming soon include Battle Creek (adult-use), Kalamazoo #1 (adult-use), Bay City (adult-use), Grand Rapids (medical), Buena Vista (medical), Center Line (medical), Kalamazoo #2 (Cookies establishment – adult-use) and Lenox Township.

The company offers delivery within a one-hour radius of its dispensaries – a footprint that encompasses an estimated 90% of Michigan’s population.

Financial Highlights

In Q1 2020, the company recorded sales of $5.8 million. This number grew substantially in Q2, reaching $11.9 million. Management estimates Q3 sales at roughly $13.1 million, marking a 157% growth in sales from January to September 2020, within a year of operations.

This increase reflects the company’s significant expansion efforts since the beginning of 2020. Starting with only 200 pounds per month, Gage now estimates its monthly cultivation capacity at more than 1,000 pounds of product.

This increase in cultivation capacity has helped Gage promote rapid growth through its retail locations. Average basket size, which refers to the retail value of each consumer transaction, is estimated at $85 for the Michigan cannabis industry. As of August 2020, Gage has an average basket size of $180 at its locations, more than double the state average.

Michigan Medical and Adult-Use Marijuana Market Size

The recreational marijuana market in Michigan is expected to rival the numbers currently seen in Nevada and Colorado by 2023. Approximately 3% of Michigan’s residents are medical marijuana cardholders – a much higher rate than many other medical markets – leading Brightfield to predict that the state’s recreational market could triple in size between 2020 and 2023 (https://ibn.fm/9cO0h).

Michigan saw a steady increase in sales for the first three quarters of 2020, with a recorded growth rate of 502% from January to August. In August alone, $109 million in cannabis sales occurred within the state. The Marijuana Regulatory Agency estimates that the potential market size for cannabis within the state is around $3 billion.

Neither Gage nor the state has seen any significant drop in sales in the wake of the COVID-19 pandemic. On the contrary, demand has continued to grow steadily, as dispensaries were among the few businesses deemed essential and permitted to operate throughout the shutdown. All Gage and Cookies locations have remained operational, offering curbside pickup.

Plans to Go Public in Q1 2021

Gage Cannabis is currently planning a Canadian listing for the first quarter of 2021 (https://ibn.fm/V73dL). Additionally, Gage intends to launch a Regulation A+ offering of up to 28,571,400 subordinate voting shares priced at $1.75 per share, for gross proceeds of up to $50 million before offering expenses, assuming all shares are sold (https://ibn.fm/FteTi), but it has not yet made an announcement regarding the launch of that financing.

A Regulation A+ offering, also called a mini-IPO, allows companies to raise capital without actually listing shares on a stock exchange.

Management Team

Bruce Linton is the Executive Chairman of Gage Cannabis. He joined the company in 2019 and is the founder and former CEO and Chairman of Canopy Growth Corp. (TSX: WEED) (NYSE: CGC). Mr. Linton has extensive executive and board experience in a variety of industries and is considered to be a pioneer in the global cannabis industry. He provides incomparable support to the company’s strategic and capital markets efforts.

Michael Hermiz is the Co-Founder and Director of Gage Cannabis, and he is also the founder of a federally licensed producer in Canada. Mr. Hermiz has had great success in various industries, including real estate, mortgage, telecommunications, import, export and many others.

Fabian Monaco is Gage’s President and Director. He previously worked at XIB Financial Inc., GMP Securities L.P. and Scotiabank. In addition to his vast investment banking and legal background, Mr. Monaco has 10+ years of capital markets experience. His advisory experience in the cannabis industry is also extensive.

Dr. Rana Harb is a Director of Gage Cannabis. She has 25+ years of experience handling research, compliance, quality assurance and regulatory affairs. A significant portion of her regulatory and compliance history is in the cannabis industry. Dr. Harb has worked for many pharmaceutical companies worldwide, dealing with regulatory agencies such as the FDA, the EMA and Health Canada.

Mike Finos is the President (USA) and a Director of Gage Cannabis. He is the former COO of Horizon Global, the world’s number one towing accessories company. He has experience with start-ups, M&A and business integration with both private and publicly traded companies. With 20+ years of operational leadership expertise, Mr. Finos has extensive knowledge relating to supply chain logistics, manufacturing and information technology.

David Watza is the Chief Financial Officer of Gage Cannabis. He is an experienced C-Suite executive and former CFO and board member of Perceptron Inc. (NASDAQ: PRCP). Mr. Watza has 30+ years of experience in finance, accounting, and operations, including time as a public company CFO.


Recent News

chart

Hemptown USA

The QualityStocks Daily Newsletter would like to spotlight Hemptown USA.

Hemptown Organics, a privately held British Columbia company, on Thursday announced its entry into a non-binding letter of intent (“LOI”) with Global Fund LLC. The LOI is regarding a potential US$8 million investment into Hemptown Organics by Global Fund via its newly established “Global Bio Solution Fund I” (the “financing”). According to the update, under the terms of the LOI, Global Fund has agreed, subject to due diligence and entry into definitive agreements, to subscribe for an aggregate of 5,714,285 units of Hemptown Organics, each at a price of US$1.40, for minimum gross proceeds of US$8 million (the “original investment”). To view the full press release, visit https://ibn.fm/PbgrW

Hemptown USA, headquartered in Central Point, Oregon, is a proven grower of full-spectrum hemp biomass grown using premium seed genetics that contain less than 0.3% THC and exceptionally high cannabinoid (CBD) content of up to 20%. The company's "soil to oil" methodology combines seasoned professionals working in hand-picked agricultural microclimates located in Oregon's famed Emerald Triangle, Kentucky and Colorado.

Hemptown has exclusive rights to 1 million rare CBG (cannabigerol) seeds genetically programmed to yield from 15% to 20% full-spectrum non-intoxicating cannabinoids. As a result of a long-standing relationship with the one of the world's most respected cannabis breeding companies — Oregon CBD Seeds — Hemptown is positioned to be a leading CBG producer in the U.S. in 2019 and beyond.

In 2018 Hemptown's harvest from its Oregon hemp farm was 150,000 pounds of full-spectrum biomass with CBD content hovering around 17%. 2018 harvest revenue expected to range from $8.1 million to $12.6 million. The company is scaling up operations in 2019 to meet market demands and projects it will reap over 1,000,000 pounds. By 2020, Hemptown projects potential revenues in the $100 million to $200 million range are possible once additional farming operations are at full strength.

Growth Strategy

By 2020, Hemptown anticipates it will have more than 3,000 acres in several states dedicated to hemp farming. Expansion plans include increasing in-house extraction capabilities to boost profit margins by providing additional CBD and CBG isolates and distillation services. Development of business-to-business channels as well as new products and formulations for the direct-to-consumer market, along with several strategic acquisitions, are also key to Hemptown's growth strategy.

Hemptown plans to expand distribution and growing operations globally through strategic partnerships and development of contracts with leading Fortune 500 brands in European markets. The company intends to grow its IP portfolio by developing a proprietary water-soluble cannabinoid delivery system. Not to be confused with water-compatibility, water-soluble cannabinoids combine seamlessly with other liquids, have a superior shelf life, and deliver dramatically increased efficacy to the consumer.

Branded Products

Hemptown's first in-house branded product line combines the inspiring strength found in the unbridled nature that surrounds the company's original hemp farm in the Siskiyou Klamath region of Oregon. Sisku is set to redefine the cannabinoid packaged goods space with an elegant look, clean feel and potent, reliable efficacy.

Custom product lines can also be created for any product manufacturer as Hemptown brings GMP and ISO accredited processing facilities online in 2019. Together with Oregon CBD Seeds and Hemptown's product sciences team, Hemptown will be able to create custom, proprietary full-spectrum CBD and CBG oils and pure isolates.

Management Team

Company Chairman Rod Wolterman founded Hemptown's Oregon operations in 2016. He has extensive experience in the cannabis sector having been active within the space since 1998. Wolterman has also acted as a private equity investor in numerous medical marijuana dispensaries and cultivation operations in southern California.

CEO John Cummings has over 20 years of experience in finance, marketing, sales and project management. He led the compliance and special projects efforts for Kings Garden, one of the largest vertically integrated operators in California. Cummings also spent a year in Europe launching the continent's first GMP and ISO-accredited cultivation and manufacturing facility.

Dr. Gordon Chiu is chief science officer for Hemptown USA. He has more than 15 years of combined domestic and international experience in biomedical, chemical, cosmetic, medical and technology industries. A graduate of Rensselaer Polytechnic Institute with a master's degree from Seton Hall University, Chiu is leading Hemptown's cannabinoid research team and is responsible for filing IP patents, specifically in the areas of water-solubility, bioavailability and peptide sequencing.


Recent News

chart

Pac Roots Cannabis Corp. (CSE: PACR)

The QualityStocks Daily Newsletter would like to spotlight Pac Roots Cannabis Corp. (PACR).

New research from investment bank UBS indicates that electric vehicles (“EVs”) may be as cheap to manufacture as regular models within the next four years (https://ibn.fm/UV8WX). This news bodes well for Net Element Inc. (NASDAQ: NETE), a global financial technology and value-added solutions group that recently announced its planned entry into the EV space through an upcoming merger with privately held Mullen Technologies Inc. (https://ibn.fm/xBu5G). Also today, the company was featured in a publication from Green Car Stocks, examining how, since it started selling its all-electric roadster more than a decade ago, Tesla has dominated the electric vehicle (EV) market. The firm has seen exponential growth over the years, eventually gaining a market valuation of more than $300 billion. But while investors have been salivating for Tesla stock for a while now, other EV makers have not been so lucky. In fact, players in the young EV industry have had a relatively hard time securing capital.

Pac Roots Cannabis Corp. (CSE: PACR) is a Canadian cannabis company dedicated to producing premium-quality strains and products by leveraging a genetics-focused approach.

The company began operations in 2012, with activities primarily directed toward exploration and development of mineral properties in Canada. Today, it is focused on cannabis and hemp cultivation, leveraging high-end genetics and specialized cultivars to produce top quality products. Pac Roots has announced multiple promising initiatives in recent months, including its formation of an outdoor premium hemp joint venture with partner Rock Creek Farms in British Columbia, Canada, and its agreement to acquire all issued and outstanding shares of a firm holding 250 acres of land in the famed Fraser Valley Region of British Columbia.

Pac Roots is also in the process of completing its 20,000 square foot cultivation facility in Lake Country, British Columbia. The facility is expected to feature approximately 7,600 square feet of cultivation space that will enable the company to cycle through an elite line of 350+ unique, high-grade cultivars. Pac Roots expects to receive a cultivation license for the facility in the fourth quarter of 2020.

High-End Selectively Bred Genetics

Pac Roots focuses on high-end genetics in order to maximize the quality of its products while maintaining high yields and profit margins.

Through the process of artificial selection, farmers and cultivators have been adapting their plants to develop particular phenotypic traits for generations. Historically, this practice was restricted to underground cannabis producers developing their own strains.

The legalization of the cannabis industry has given producers access to thousands of cultivars located throughout the world while accelerating research into cannabis genetics. By carefully selecting strains, growers can control the size, color, smell, density and texture of cannabis buds, thereby creating distinctive, premium cannabis products.

Plants are bred to thrive in specific growing environments. This maximizes the yield of high-quality, resilient cannabis. Medical cannabis strains can also be tailored for specific medicinal purposes.

A strategic partnership with Phenome One, a plant breeding management and analytics firm, gives Pac Roots access to some of the world’s best cannabis genetics from the largest genetic library in Canada. The company is using these genetics to develop unique strains featuring a variety of beneficial characteristics.

The company’s 350+ licensed live cultivars and over 1,800 seed varieties are the result of a meticulous gene selection process, through which as many as 600 individual plants may be grown to produce a single strain. Selecting optimized genetics in this way provides benefits beyond simply producing a high-end product. In addition to potency and bud quality, cannabis plants are bred for yield and resilience. By selecting genetics that result in larger and more numerous buds on each plant, Pac Roots is able to grow more cannabis per grow light.

Breeding plants to be more resilient also reduces the cost and labor required. These factors, combined with the premium price point associated with top-quality cannabis, have the potential to improve Pac Roots’ overall profit margin.

Partnership with Phenome One

Pac Roots has secured its cultivars through a strategic licensing agreement with Phenome One. Under the agreement, Pac Roots has unlimited access to Phenome One’s live genetic library, including any of Phenome One’s cultivars and its growing, breeding and cloning IP.

Phenome One is an agricultural technology company focused on providing software solutions to seed companies. Phenome One’s platform gives its partners access to a massive database of detailed information on over 350 unique cannabis cultivars to support each stage of the breeding process. Each cultivar has been laboratory analyzed and rigorously field-tested, with data going back more than 30 years.

Using Phenome One’s data, Pac Roots plans to grow a variety of cannabis plants optimized for certain traits. One such trait will be plants with an abundance of cannaflavin, a rare terpene with high anti-inflammatory properties. Phenome One’s library could enable Pac Roots to produce plants that are bred to thrive in a range of different growing climates, including plants suited to grow in cold weather and plants that are resilient to region-specific fungi.

Joint Venture with Rock Creek Farms of British Columbia

Pac Roots recently entered a definitive investment agreement with Rock Creek Farms, a reputable agricultural enterprise, for a 100-acre commercial hemp operation in Rock Creek, British Columbia. The growing space is located in the highly lucrative farming area known as the ‘Golden Mile’ in the South Okanagan Valley of British Columbia. (http://nnw.fm/Gbf9I).

Under the agreement, the two companies have formed an outdoor premium hemp joint venture company to which Pac Roots is providing an aggregate of $450,000 in capital and Rock Creek Farms is contributing two commercial leases for 100+ acres of growing space, along with cultivation licenses, agricultural infrastructure and equipment, consulting services, intellectual property relating to hemp operations and proprietary biomass storage methods. Pac Roots holds a 60 percent interest in the project.

About 127,500 premium hemp CBD seedlings were planted across 100 acres as of early July 2020. The joint venture is planting a premium grade CBD hemp variety utilizing the rich native soil and both traditional and custom farming techniques.

“Our operational partners at Rock Creek Farms bring decades of generational farming expertise in one of Canada’s pre-eminent growing regions,” Pac Roots President and CEO Patrick Elliott said in a news release detailing the venture. “It will be an exciting outdoor growing season for the joint venture as we anticipate a successful harvest in the fall.”

Infinite Development Possibilities at Fraser Valley Property in British Columbia

In mid-July 2020, the company initiated a share purchase agreement with 1088070 BC. LTD. (“1088”) and its shareholders for the acquisition of all issued and outstanding shares of 1088 (http://nnw.fm/xlpw7). Notably, 1088 owns and controls 250 acres of land spread over nine parcels in the Fraser Valley Regional District.

The Fraser Valley Regional District is one of the most productive and intensively farmed areas of Canada, offering access to high-quality soil, favorable climate, water and a local market of 2.5 million people. Agriculture in this region yields an annual economic value of more than $3 billion.

The closing date for the transaction is slated for September 4, 2020, after a 51-day due diligence period. According to Elliott, the addition of such a significant package of land is a major step for Pac Roots.

“This land has no zoning restrictions and is not situated within the agricultural land reserve, which provides for infinite development possibilities,” Elliott added in a July 2020 news release.

Board of Directors member Chad Clelland also welcomed the acquisition, adding that between Fraser Valley and Rock Creek – both of them among the most productive agricultural regions in Canada – Pac Roots is very well positioned for production and the future development of its hemp and cannabis infrastructure.

The RAD Americas Genetic Program – Research and Development in Americas Genetic Program

Pac Roots intends to deploy a global R&D program focused on rigorously testing elite strains in various rich agricultural regions throughout the Americas, with a goal of mass selection to achieve the utmost environmental resilience while achieving notable quality and yields. From seed to software, collection data, proprietary techniques and custom nutrient formulas, Pac Roots and Phenome will provide the specific knowledge to cultivators in different climates in order to achieve optimal yields for THC, CBD, CBG and other unique cannabinoids. R&D from global testing programs situated throughout the Americas will allow the partnership to deploy and stress test a range of suitable cultivars in the world’s lowest cost outdoor growing regions.

The company expects an industry shift in 2020 from the COVID-19 global pandemic. The ‘new normal’ will bring more focus on efficiencies and optimal yields to deliver a cost effective, high quality product to the end user. There has been much to be learnt from the inefficiencies in the cannabis industry in recent years, which have been detrimental to the credibility of the sector. Pac Roots is well positioned to enter the scene and take advantage of the deficiencies, reinforcing the notion that genetics and flawless growing techniques are paramount to success. Genetics and systems innovation may be the most overlooked components when comparing cannabis to other established agricultural crops. Pac Roots plans to invest into cannabis R&D to ensure a solid foundation is built that will be used by cannabis farmers worldwide.

Through its RAD Americas Development and Innovation, Pac Roots is focused on:

  • Deploying one of the largest live genetic libraries in Canada, diversified for high yield output and unique climates
  • Continued stress testing for indoor, high yield, THC and medicinal genetics
  • Continued stress testing for outdoor, high yield, THC and medicinal genetics
  • Exotic, genetic cloning for the luxury, high margin, cannabis flower market
  • Psychoactive/medicinal ratio testing for effect and
  • Unique Cannabinoid and terpene elevation and isolation.

Through its RAD Americas Field Testing System, the company is focused on:

  • Global testing in different microclimates to assess genetic and complete systems for optimal yields
  • Data collection, testing and optimization to prove process for commercial implementation and
  • High quality yield testing for THC, CBD, CBG and other unique medicinal cannabinoids.

Lake Country Cultivation Facility near Kelowna, British Columbia

Pac Roots is in the process of completing its 20,000 square foot cultivation facility in Lake Country, British Columbia. The facility is expected to feature approximately 7,600 square feet of cultivation space that will enable the company to cycle through its line of high-grade cultivars. Pac Roots plans to submit a video evidence package of the facility build under Health Canada’s Cannabis Tracking and Licensing System, and the company expects to acquire its cultivation license in the fourth quarter of 2020.

Lake Country is a municipality located just outside of Kelowna in the Okanagan region of British Columbia. For decades, the region’s favorable growing climate has made it a hub for cannabis cultivation. As the Canadian legal cannabis industry ramps up, the Okanagan region is attracting attention from dozens of cannabis companies, including some of the industry’s biggest names. The region’s strong agricultural history has left it rich with experienced agricultural workers and an abundance of Agricultural Land Reserve (ALR) property.

Management Team

Patrick Elliott, MSC, MBA, President and CEO of Pac Roots Cannabis, is also the President & CEO of Lexore Capital Corp., a private resource and cannabis investment company, as well as Phenome One Corp., a full-service cannabis farming company focused on elite strain selective breeding. Elliott brings over 15 years of corporate finance, mineral exploration and financial markets experience to the Pac Roots team. He is a graduate of the University of Western Ontario in geology and holds an MSc. in mineral economics and an MBA from Curtin University of Technology in Perth, Australia. Elliott specializes in economic resource evaluation, financial modeling, CAPEX estimation, corporate development and finance. Combined with his technical knowledge, Elliott has a wealth of contacts in the financial sector.

Marc Geen, Founder and Strategic Operations Advisor, is a fourth-generation British Columbia farmer who has been active in the legal medical marijuana industry for more than 10 years – consulting on, complying with, and participating in the MMAR, MMPR and ACMPR programs. Prior to co-founding Speakeasy Cannabis Club Ltd., Geen spent 14 years as Head of Operations for Kettle Mountain Ginseng Ltd., one of North America’s largest ginseng producers. With the experience gleaned from a long career in large scale commercial farming, Geen has been able to apply many cost-effective farming practices to the outdoor, indoor and greenhouse cultivation of cannabis. Geen is also the co-creator of a full line of cannabis extract products designed under ACMPR regulations.

Matt McGill, Director, has a strong background in both commercial and residential real estate and has played a major role in many development projects. McGill, through McGill Realty, has established a tremendous commercial and residential outfit servicing British Columbia’s Fraser Valley and the lower mainland. McGill is skilled at crafting strategic financing options for corporations and has a substantial network of retail and institutional clients.

Chad Clelland, Director, has experience in the sector dating back to 2009, when he purchased Medicalmarijuana.ca, which became an information portal for thousands of patients, doctors and growers. Through this company, he and his team have helped thousands of Canadians find legal, safe medication. His team also consulted, designed and submitted dozens of applications to the government under the MMPR, ACMPR and Cannabis Act. In 2011, Clelland co-founded Greenleaf Medical Clinic, which is now recognized as a training facility by the University of British Columbia and offers preceptorships to physicians, nurse practitioners and pharmacists. He also co-founded Folium Life Science in 2013, an approved Canadian Licensed Producer. His roles in these organizations have included Chief Operating Officer, head of security, alternate master grower and alternate responsible person in charge.

Josh Bromley, Senior Cultivation Strategist, is a second-generation farmer with over two decades of experience farming, breeding, cultivating and selecting unique cultivars for the medical community. He is an expert in plant science and possesses a comprehensive knowledge of cultivars and a mastery of medicinal implementation. Bromley has developed proprietary farming systems, as well as low cost/high output nutrient systems. Through thoughtful design and engineering, he has been able to consistently show improvements in crop yields, pathogen resiliency and quality.

Pac Roots Cannabis Corp. (PACR), closed Friday's trading session at $0.18, even for the day. The average volume for the last 3 months is 11,610 and the stock's 52-week low/high is $0.11/$0.72.

Recent News

Sigma Labs Inc. (NASDAQ: SGLB)

The QualityStocks Daily Newsletter would like to spotlight Sigma Labs Inc. (SGLB).

Sigma Labs (NASDAQ: SGLB), a leading developer of in-process quality assurance software for the commercial 3D metal printing industry, on Thursday released its financial and operational results for the third quarter ended September 30, 2020. To view the full press release, visit https://ibn.fm/ISZID

Sigma Labs Inc. (SGLB) is the only provider of in-process quality-assurance software to the commercial 3D printing metal industry that enables operators of machines making 3D metal parts to offset emerging quality problems, sustain part quality, and avoid rejects. Sigma’s software is the singular solution that enables both real-time, in-process detection of quality control manufacturing irregularities for critical metal parts and then provides the operator the actionable information needed to adjust and mitigate the developing anomaly. Sigma Labs’ software represents a paradigm shift in the quality control process for the manufacture of 3D printed metal components. The nascent 3D metal printing industry is on the verge of radically altering the speed and technical complexity of manufactured parts. Further, it makes possible just-in-time availability of critical components – all at reduced cost, time, waste and weight. 3D printing, heralded as the fourth industrial revolution in manufacturing, will only truly surpass traditional techniques when the additive manufacturing industry moves from “post process” quality control to “in process” quality assurance.

For the industry to move from prototype manufacturing of critical components to economically viable commercial production, the 3D metal printing industry must find ways to dramatically increase production speed and quality yields, and to dramatically decrease the excessive cost of quality control. To achieve these prerequisites and move 3D metal printing into the mainstream, parts must be inspected and certified during the manufacturing process rather than after. Parts in the production process that are developing signs of quality control problems must be identified in real-time and alerts must be issued. The problem, along with the solution, must then be communicated to the machine operator to implement repairs.

Revolutionizing Additive Manufacturing

Sigma Labs, with its PrintRite3D® brand, has established a new benchmark in the development and commercialization of real-time computer aided inspection (“CAI”) solutions. Sigma Labs resolves the major roadblocks and costly quality control challenges that impede the 3D manufacture of precision metal parts. The company’s breakthrough computer-aided software product revolutionizes commercial additive manufacturing, enabling non-destructive quality assurance during production, uniquely allowing errors to be corrected in real-time.

Sigma Labs was founded in 2010 by a team of Los Alamos National Labs scientists and engineers to develop and commercially license advanced metallurgical products for the military ordinance, dental implants, and then for additive manufacturing (3D printing). After assessing 3D metal printing technology and the costly, inconsistent quality control issues, Sigma Labs concluded that the enormous potential of 3D metal printing could only scale up if in-process quality-assurance tools were developed to observe, manage and control the manufacturing complexities in such a manner that reliability and repeatability of very high precision quality metal parts could be achieved in the process. Sigma Labs’ patented and third-party validated software has achieved these objectives and now delivers the critical elements needed to unleash the promise of 3D metal printing.

Sigma Labs’ products and services are engineered, manufactured and qualified for use in the highly demanding and hyper precise production environments of the aerospace, defense, transportation, oil and gas, biomedical and other precision-dependent industries.

The Challenge

Additive metal manufacturing combines multiple processes and parts into one single 3D printed part. Due to variances in the additive manufacturing process, parts of consistent quality currently can’t be reliably produced in either large or small quantities without substantial postproduction inspection and rejection costs. Parts are inspected after production using CT scans and other means, so the manufacturer doesn’t know until the very end which of the finished parts meet design specifications. This means lost time, lost profits and inability to economically scale up production.

Innovative Approach

Sigma Labs solves this problem with its patented, in-process quality control technology that informs operators and engineers how to improve both the manufacturing process and quality by capturing meaningful data about inconsistencies in real-time. Sigma Labs is also partnering with OEMs, working toward the visionary introduction of revolutionary closed-loop control that will bypass the machine operator and automatically make in process corrections by reducing machine variations.

Sigma Labs’ next generation technology gives manufacturers the ability to make fast, virtual real-time adjustments so that each finished part is uniform and within critical specifications, thereby improving production quality, decreasing end-users’ risks and waste, and increasing profits and speed to market. Sigma Labs’ PrintRite3D® IPQA Software monitors and assesses the quality of each production part in the 3D additive manufacturing process – layer by layer, and in real-time. This has never been available until now.

Sigma Labs maintains a strong intellectual property portfolio consisting of trade secrets, process know-how and 34 patents either granted, pending or awaiting pre-publication around the globe. These patents encompass the fundamental technologies underlying Sigma Labs’ melt pool process control, data analytics, anomaly detection, signature identification, and future “closed-loop control” of 3D metal printing.

Market Opportunity

Providing advanced quality assurance software to the commercial 3D printing industry is currently a $1.4 billion addressable market expected to grow to $3.9 billion by 2023. Integrating Sigma Labs’ groundbreaking software helps arm the industry with a necessary catalyst to help enable and optimize the fourth industrial revolution in manufacturing.

Sigma Labs’ global client base includes 23 installations across 19 different users. Tier-1 OEM enterprises and end-users such as Siemens, Honeywell, Pratt & Whitney and others are currently evaluating PrintRite3D® for production lines.

Management Team

John Rice, CEO and chairman of the board of directors, has extensive experience as a CEO, lead negotiator, turnaround expert, business financier and crisis management executive/consultant. Prior to becoming chair and CEO of Sigma Labs, he was the CEO of a successful turn-around of a Coca-Cola Bottling Company. Rice has led a variety of companies in diverse business sectors and worked on a host of products and technologies including design and manufacture of high-end jet engine test equipment for the U.S. Airforce, chaff dispensers for F16s, software for modeling naval exercises, software for controlling warehouse distribution systems, medical radioisotopes, cancer detection, and cybersecurity. He is an honor’s graduate of Harvard College.

Darren Beckett, CTO, has over 20 years of experience in the semiconductor industry, including Intel Corporation, where he held various technical and managerial positions. His expertise in process engineering for advanced manufacturing technology includes statistical process control for fabrication of semiconductor devices.

CFO Frank D. Orzechowski also serves as treasurer, principal accounting officer, principal financial officer and corporate secretary. He has more than 30 years of distinguished financial and operational experience. Orzechowski began his career at Coopers & Lybrand in 1982, received his CPA certification in 1984, and received his Bachelor of Science in Business Administration with a major in accounting from Georgetown University in 1982.

Ronald Fisher, vice president of business development, is leading the commercialization of PrintRite3D® 5.0. Fisher is a mechanical engineer with hands-on experience in quality, manufacturing and product development. He has distinguished himself as a lead sales and marketing officer as well as a chief operating officer most recently before joining Sigma in technology startup that grew from market entry to successful exit by merger-acquisition.

Sigma Labs Inc. (SGLB), closed Friday's trading session at $2.44, off by 15.8621%, on 722,555 volume with 2,237 trades. The average volume for the last 3 months is 1,443,096 and the stock's 52-week low/high is $1.95000004/$11.6999998.

Recent News

Siyata Mobile Inc. (NASDAQ: SYTA) (TSXV: SIM)

The QualityStocks Daily Newsletter would like to spotlight Siyata Mobile Inc. (SYTA).

Siyata Mobile (NASDAQ: SYTA, SYTAW), a business-to-business (“B2B”) global vendor of next-generation cellular solutions, on Thursday announced that management will host a live investor webinar to review the company’s updated October investor presentation. The event is scheduled to take place at 2:00 p.m. ET on Thursday, October 29, 2020. Management will provide an overview of current operations, industry metrics and upcoming milestones on Siyata’s products (rugged handsets, in-vehicle devices and cellular boosters). Interested parties may register for the event by visiting https://ibn.fm/HaqWA. To view the full press release, visit http://ibn.fm/63UZE

Siyata Mobile Inc. (NASDAQ: SYTA) (TSXV: SIM) is a leading global developer and provider of Push-to-Talk Over Cellular (“PTT/PoC”) systems for enterprise customers. The company specializes in connected vehicle products for professional fleets and markets its products under the Uniden® Cellular brand.

Since its inception in 2012, Siyata has amassed a customer base that includes cellular operators, commercial vehicle technology distributors, and fleets of all sizes in Canada, the U.S., Europe, Australia and the Middle East.

Recognized by the Toronto Venture Stock Exchange in 2018 as a Venture Top 50 Company, Siyata aims to deliver the highest quality and most technologically advanced mobile communication devices for global corporate workforces, fleets, homes and buildings.

The company has long been an industry pioneer, delivering the world’s first 3G connected vehicle device as well as the world’s first 4G/LTE vehicle-mounted smartphone for First Responders and commercial fleets and vehicles, thereby creating a new category in the cellular device market with a dedicated smartphone tailor-made for the commercial vehicle market.

Siyata is headquartered in Montréal, Québec, Canada.

Product Portfolio

Siyata’s suite of technology includes numerous PTT and legacy devices, as well as cellular boosters designed to improve cellular signals in corporate warehouses, government embassies, retirement home campuses, banks and manufacturing plants.

The company’s flagship product, the Uniden UV350, is the world’s first vehicle-mounted 4G/LTE smartphone with crystal clear quality, carrier grade PTT, voice, text, video and data applications built into a single device. Specifically designed for First Responder and commercial fleet vehicles, the UV350 runs on cellular LTE networks that provide nationwide and global coverage, replacing traditional single purpose two-way radios that require a monthly fee and limited network coverage.

The Uniden UV350 is currently available through Bell Mobility, Canada’s largest LTE network and PTT community, as well as AT&T in the U.S. Further expanding its availability, Siyata is completing network approval with another U.S. Tier 1 operator to launch the UV350 in Q3 2019.

Management Team

CEO and Chairman Marc Seelenfreund is the founder of Siyata. He is also the founder of Siyata’s parent company, Accel Telecom, an Israel-based company that specializes in importing and distributing innovative cellular and IP devices to fixed line operators and mobile providers within Israel. Prior to establishing Accel, Seelenfreund was a vice president at Sunrise Corporation in New York where he focused on financing publicly traded technology companies. Seelenfreund has a law degree from Bar Ilan University, is a board member at Israel’s leading private university, and has served as an officer in the Israel Defense Forces.

Glenn Kennedy, vice president of sales, has over 25 years of sales experience in the telecommunications industry. Prior to joining Siyata in 2016, Kennedy managed sales nationally for Motorola Canada, HTC Communications Canada, and Sonim Technologies. He holds a bachelor’s degree in honors business administration from the Richard Ivey School of Business at the University of Western Ontario.

CFO Gerald Bernstein, a professional chartered accountant, has spent 20 years focusing on private equity financing and tax efficient corporate structuring in multi-jurisdictional arenas. He holds a bachelor’s degree of commerce as well as a graduate diploma in public accountancy from McGill University. Bernstein has been a member of the Canadian Institute of Chartered Accountants since 1987.

Gidi Bracha, vice president of technology, has served in this position since 2011 and spearheaded the development of both the Truckfone, Voyager and UV350. Bracha served in various key positions at Cellcom, Israel’s leading cellular provider, including head of car mobility products and director of type approvals. Bracha served as an engineer technician in the Anti-Aircraft division of the Air Force in the Israel Defense Forces and holds a bachelor’s degree in engineering and business management from the University of Derby.

Siyata Mobile Inc. (SYTA), closed Friday's trading session at $5.35, up 0.753296%, on 32,985 volume with 109 trades. The average volume for the last 3 months is 80,415 and the stock's 52-week low/high is $3.90000009/$5.50.

Recent News

PowerBand Solutions Inc. (TSXV: PBX) (OTCQB: PWWBF) (Frankfurt: 1ZVA)

The QualityStocks Daily Newsletter would like to spotlight PowerBand Solutions Inc. (TSXV: PBX) (OTCQB: PWWBF) (Frankfurt: 1ZVA).

PowerBand Solutions (TSX.V: PBX) (OTCQB: PWWBF) (Frankfurt: 1ZVA), a fintech provider disrupting the automotive industry, was selected by Premier Auto Group, one of the fastest growing auto dealership networks in the U.S. for the signing of Premier Auto’s dealers onto PowerBand’s virtual transaction platform, DRIVRZ. According to the update, with sales from its 24 dealerships nearing US$1 billion, Premier Auto's dealers will have access to the DRIVRZ virtual transaction platform and 4.5 million new and used cars. To view the full press release, visit http://ibn.fm/9lT7N

PowerBand Solutions Inc. (TSXV: PBX) (OTCQB: PWWBF) (Frankfurt: 1ZVA) is revolutionizing the world’s automotive industry with a cloud-based platform that makes buying, selling, leasing and trading cars and trucks as easy as purchasing a product on Amazon or ordering an Uber from a smart phone. PowerBand offers auction and finance portal software tools that increases sales, efficiencies and profitability to its customers and dealers. It provides a transparent, simple, buy-sell online-auction and inventory-management system.

A Better Way to Connect and Acquire Vehicles

PowerBand’s mission is to create an online, consumer-directed marketplace that streamlines the interactions among all participants in the automotive industry. It transforms today’s antiquated business model with speed, transparency, access to information and ease of use for consumers and dealers.

Consumers can easily connect with new sources to buy vehicles, network with motivated buyers and sellers, maximize their trade-in values, improve their customer experience. PowerBand’s standardized system and transaction process also increase efficiencies and benefits with hands-on, process-driven, in-store training and support.

Through internal development, acquisitions, joint ventures and strategic partnerships, PowerBand is developing solutions for consumers, dealers, manufacturers, commercial customers and lenders that are poised to transform the trillion-dollar U.S. automotive industry.

The PowerBand Auto Platform

PowerBand’s transaction platform was developed by a team of experienced automotive, technology and finance experts, and has been refined through years of operational experience. Built on the core belief that the consumer prefers to primarily conduct automotive transactions online and avoid interactions with unnecessary middlemen, PowerBand’s product solutions include:

  • Leasing: PowerBand is currently licensed in 33 U.S. states via a majority interest in MUSA Auto Finance LLC, an advanced online leasing technology platform that has transformed the new and used vehicle leasing industry. MUSA is the only approved, non-captive lease partner for Tesla in the U.S., and the platform can approve leases in a matter of seconds.
  • Inventory and Financing: A partnership with RouteOne LLC, a leading financial platform founded in 2002 by Ally Financial, Ford Motor Credit Co., TD Auto Finance and Toyota Financial Services, allows access to a network of more than 18,000 dealerships and 1,400 financing sources.
  • Auction Platform: PowerBand and its joint-venture partner, D2D Auto Auctions, are developing a direct consumer-to-dealer and a consumer-to-consumer automotive portal, which will provide an innovative alternative to physical dealership and auction locations.
  • LiveNet Auction: An online platform portal that allows dealers to create instant live vehicle auctions to a vast network of the industry’s top used vehicle buyers.
  • MarketPlace Auction: An online listing auction site for buying and selling automotive inventory – ideal for dealers, fleet, OEM and rental companies.
  • Used Vehicle Inspections: An LOI agreement with TÜV NORD Mobility Inc., a German-based global leader in vehicle inspections operating in more than 70 countries, will provide the most comprehensive, certified vehicle inspection reports available in North America. Appointments booked within the platform can be performed nearly anywhere.
  • Product Development: PowerBand’s comprehensive consumer solution, Driveaway, will be a fully transactional consumer marketplace where dealers and consumers can buy, sell, trade-in and finance vehicles, often in seconds, from the comfort of their home.

Automotive’s Growing Markets

The automotive dealership and commercial fleet vehicle auction industry is a $100-billion sector with more than 40 million used vehicles transacted in the U.S. each year. Of those, ten million are sold through auctions. From 2013 to 2017, the growth of online-only auctions far outpaced physical auctions, growing at a 33% compound annual growth rate compared to 2% CAGR at physical auctions.

Automotive leasing is another large, growing and fragmented market, generating approximately $120-billion in annual revenue. As a percentage of vehicle sales, leasing reached 30% in 2018, up from 21% in 2012, and is seen as a substantial opportunity for PowerBand and MUSA Auto Finance. Using proprietary technology and by focusing on high-quality, credit-worthy customers, MUSA grew its automotive lease originations to $182 million.

Disrupting Auto Leasing with MUSA

Legacy solutions are complicated, expensive and slow at processing leases. MUSA’s first-of-its-kind technology platform eliminates third-party decisions and the human capital required in the underwriting process. MUSA’s platform navigates the entire customer experience – underwriting, funding and the delivery process – within minutes. Leases can be approved in seconds.

PowerBand’s acquisition of MUSA brings together two leading-edge companies with the vision to become a one-stop platform for the entire vehicle purchase lifecycle.

Experienced Leadership

PowerBand is led by a collection of automotive veterans with a passion to collectively and positively impact the industry.

  • Kelly Jennings, president and CEO, is the founder of PowerBand Solutions and a franchise dealer owner/operator with more than 27 years of automotive experience. Jennings received General Motor’s Triple Crown Award, Ford Motor Company President’s Award and Honda Canada’s Excellence Award.
  • Darrin Swenson, COO of PowerBand and D2D Auto Auctions/Hunt Automotive Group, has more than 25 years of automotive/auction experience.
  • Jeff Morgan, CEO MUSA, holds over 25 years of experience in the auto finance sector.

PowerBand Solutions Inc. (OTCQB: PWWBF), closed Friday's trading session at $0.18, even for the day, on 65,208 volume with 3 trades. The average volume for the last 3 months is 44,430 and the stock's 52-week low/high is $0.038600001/$0.241600006.

Recent News

Exro Technologies Inc. (CSE: XRO) (OTCQB: EXROF)

The QualityStocks Daily Newsletter would like to spotlight Exro Technologies Inc. (OTCQB: EXROF).

Exro Technologies (TSX.V: EXRO) (OTCQB: EXROF), a leading technology company that has developed a new class of power electronics for electric motors and powertrains, on Thursday joined TMX Group’s Head of Company Services Berk Sumen for a virtual broadcast. Exro CEO Sue Ozdemir and her team joined Sumen to celebrate the company's new listing on TSX Venture Exchange and to open the market for the day’s trading. To view the virtual broadcast, visit http://ibn.fm/4cXri

Exro Technologies Inc. (CSE: XRO) (OTCQB: EXROF), a Canadian technology company, is an innovative pioneer in the energy sector. Exro has developed and commercialized an electric power module (EPM) that integrates into existing motor systems to make them smarter. Exro’s patented technology optimizes existing motor performance by automatically sensing and adapting operating parameters to an optimized state, creating measurable efficiency gains, reduced mechanical components and increased system availability.

Applications

Exro’s technology and efficiency optimization algorithms improve the performance and efficiency of electric motors by manipulating power delivery to individual coils, thereby enabling the ability to expand operating parameters. This novel approach is scalable and can be utilized in most variable torque applications.

The widespread applications of Exro’s technology apply to optimizing the performance of electric vehicles, locomotive traction applications, industrial motors, and other variable torque applications that benefit from smart energy conversion.

Intellectual Property

Exro’s proprietary, patented software controls electric motor coils through individual coil switching. This introduction of intelligence into energy conversion at the level of individual coils results in expanded speed/torque capability, improved machine efficiency, reliability, safety and maintenance across a wider operating range. Exro’s advanced control algorithms create smart, real-time optimized power management.

Exro currently holds 15 patents, with 8 patents pending and additional patents under development. The company continues to expand its IP portfolio to support its goal of becoming a globally recognized leader in leveraging advanced control algorithms to improve the performance, efficiency and longevity of electric motors and generators.

Market Opportunity

Electric motors are the single biggest consumer of electricity. They account for about two-thirds of industrial power consumption and about 45% of global power consumption, according to an analysis by the International Energy Agency. Exro’s technology seeks to give industries a new way to look at energy—from electric vehicles, to industrial equipment, to renewable applications like wind farms; we are improving the way energy is consumed.

Laboratory Expansion

The 6,500-square-foot Exro Innovation Center (EIC), scheduled to open spring of 2020 in Calgary, will transition the current Victoria lab into one Calgary based center. The company’s new laboratory space will expand its service capabilities to customers, provide larger test capabilities, and showcase how Exro’s technology can be applied to dramatically improve the performance of electrical motors.

The EIC will also host collaborative events to explore advances in energy consumption and electric motor innovations, with participants from across Canada and around the world.

Strategic Partnerships

  • A strategic agreement with Finland’s Aurora Powertrains Oy, which in 2019 released an all-electric production snowmobile called the “eSled,” will see Exro’s technology added to the Aurora electric powertrain. The snowmobile sector’s economic footprint is estimated at $26 billion in the U.S., $8 billion in Canada, and $5 billion in Europe and Asia.
  • An agreement with Potencia in Mexico serving the last mile vehicle segment will integrate Exro’s custom drive and EPM module into small passenger commercial vehicles (taxis) and fleet delivery trucks
  • A licensing agreement with Motorino Electric, a leader in the Canadian electric transportation industry, will integrate Exro’s Electric Power Module technology into Motorino’s CTi electric bicycle.

Management

Chief Executive Officer Sue Ozdemir is a proven leader in the innovation and manufacturing of electric motors. She has nine years of accomplishments at General Electric, acting as CCO and the CEO of GE’s Small Industrial Motors Division, overseeing the division’s North American and international markets — ultimately building the division into a $160 million enterprise.

Chief Commercial Officer Josh Sobil is leading the seamless adoption of Exro’s growing product portfolio focused on the mobility segment and opening doors in all segments including agriculture, heavy industry, energy, construction, among others.

Executive Chairman Mark Godsy is a serial technology entrepreneur who has been involved in many top tier ventures, including two of Canada’s most successful biotech companies.

Exro Technologies Inc. (CSE: XRO) (OTCQB: EXROF), closed Friday's trading session at $2.05, off by 3.0825%, on 279,482 volume with 381 trades. The average volume for the last 3 months is 509,406 and the stock's 52-week low/high is $0.150000005/$2.86988997.

Recent News

Net Element (NASDAQ: NETE)

The QualityStocks Daily Newsletter would like to spotlight Net Element (NETE).

New research from investment bank UBS indicates that electric vehicles (“EVs”) may be as cheap to manufacture as regular models within the next four years (https://ibn.fm/UV8WX). This news bodes well for Net Element Inc. (NASDAQ: NETE), a global financial technology and value-added solutions group that recently announced its planned entry into the EV space through an upcoming merger with privately held Mullen Technologies Inc. (https://ibn.fm/xBu5G). Also today, the company was featured in a publication from Green Car Stocks, examining how, since it started selling its all-electric roadster more than a decade ago, Tesla has dominated the electric vehicle (EV) market. The firm has seen exponential growth over the years, eventually gaining a market valuation of more than $300 billion. But while investors have been salivating for Tesla stock for a while now, other EV makers have not been so lucky. In fact, players in the young EV industry have had a relatively hard time securing capital.

On June 15, 2020, Net Element announced its entry into a binding letter of intent to merge with privately-held Mullen Technologies Inc., a Southern California-based electric vehicle company, in a stock-for-stock reverse merger in which Mullen’s stockholders will receive the majority of the outstanding stock in the post-merger company. The proposed merger is currently pending the execution of a definitive agreement, shareholder vote and regulatory approval.

Net Element Inc. (NASDAQ: NETE) is a global financial technology and value-added solutions group that supports electronic payments acceptance in an omni-channel environment spanning across point-of-sale, e-commerce and mobile devices. The company operates a payments-as-a-service transactional model and value-added services platform for small to medium enterprises in the U.S. and selected emerging markets.

Net Element believes the future of global commerce is being revolutionized as consumers quickly migrate toward omni-channel shopping utilizing mobile devices, desktop, and online services. The company’s all-in-one payment solutions support and unify a whole range of applications through a single, robust platform, allowing global onboarding and support for multiple payment methods.

Net Element has also launched a blockchain-focused business unit that will develop and deploy blockchain technology-based solutions. Net Element expects the new division to create a decentralized crypto-based ecosystem that will act as a framework for an unlimited number of value-added services, connecting merchants and consumers in a seamless, economically efficient transaction. This new business unit intends to also identify and invest in unique projects that decentralize and disrupt the payment processing industry by combining blockchain technology and real-world applications with talented development teams, strong fundamentals and addressable markets large in size.

“We believe that we’re at the dawn of a new evolution where additional digital payment methods are being introduced,” Net Element chairman and CEO Oleg Firer, says. “Introduction of our division focused on blockchain as part of the NASDAQ-listed entity will add transparency and compliance assurance to our investors as well as provide access to deploy value-added services to over 20 million electronic commerce clients that are currently part of Net Element’s growing network.”

Net Element clients are treated to customized solutions that provide the flexibility needed to keep up with customers. Among the services offered are mobile payment apps that accept payments anywhere, anytime; cloud-based solutions built to increase productivity and enhance revenue for clients and partners; marketing solutions that turn lookers into buyers; and business analytics that make it easy for clients to monitor business metrics, engage with customers and compare the competition. Its multi-channel platform combines e-commerce, offline, point-of-sale, comprehensive back office tools, mobile point-of-sale, credit scoring and customer interaction in one powerful platform-as-a-service technology.

Net Element owns and operates a global mobile payments and transactional processing provider, TOT Group, Inc., with the following subsidiaries:

  • Unified Payments – An award-winning, customized mobile billing and payments solution, recognized by Inc. Magazine as the No. 1 Fastest Growing Company in America in 2012.
  • Aptito – A next-generation, all-in-one, cloud-based restaurant management and point-of-sale payments platform using wireless technology.
  • Payonline – A fully integrated, processor agnostic electronic commerce platform.

Net Element is ranked on Deloitte’s Technology Fast 500™ list of North America’s 500 fastest growing technology, media, telecommunications, life sciences and energy tech companies in both 2017 and 2018, during which the company grew 190 percent and 183 percent, respectively. The company credits its progression to organic growth in its North America Transactions Segment, specifically the success of its Unified Payments brand, which focuses on value-added payment acceptance solutions for small to medium enterprises in the United States.

Net Element was also listed among South Florida Business Journal’s 2016 fastest growing technology companies.

Leveraging its suite of application performing interfaces (APIs) and connectors, Net Element powers commerce for businesses of all sizes through multi-channel platforms, all-in-one digital solutions, and end-to-end encryption of cardholder data utilizing tamper resistant hardware that ensures integrity and simplifies security.

Leading this innovation is chairman and CEO Oleg Firer, who is responsible for the overall vision, strategy and execution of the company’s mission of powering global commerce. He is joined by CFO Jeffrey Ginsburg, CPA, and Steven Wolberg, the company’s chief legal officer and secretary. Each corporate officer brings a unique blend of leadership, vision, experience and creative energy to the company.

From mobile payments and value-added transactional innovations like Aptito to e-commerce and retail payment transaction processing brands like Payonline and Unified Payments, Net Element is transforming the online and mobile experience.

Net Element (NETE), closed Friday's trading session at $6.87, off by 0.290276%, on 205,789 volume with 1,426 trades. The average volume for the last 3 months is 1,328,973 and the stock's 52-week low/high is $1.472/$20.0783996.

Recent News

The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF)

The QualityStocks Daily Newsletter would like to spotlight The Green Organic Dutchman (OTC: TGODF).

The Green Organic Dutchman Holdings Ltd. (the "Company" or "TGOD") (TSX: TGOD) (US: TGODF), a leading producer of premium certified organically grown cannabis, is pleased to announce that it has closed its previously announced short form prospectus offering, on a bought deal basis, including the full exercise of the underwriter's over-allotment option. A total of 53,263,400 units of the Company (the "Units") at a price per Unit of $0.24 were issued for aggregate gross proceeds of approximately $12.75 million (the "Offering"). The Offering was conducted by Canaccord Genuity Corp. Also today, the company was highlighted in a publication from Investing News Network, examining how recreational cannabis sales in Canada are on the rise, according to new Statistics Canada figures.

The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF), whose principal location is in Hamilton, Ontario, produces farm grown, organic, pesticide-free medical cannabis in small batches using all natural, organic craft growing principles. TGOD is licensed under the Access to Cannabis for Medical Purposes Regulations (ACMPR) to cultivate medical cannabis. The company carries out its principal activities producing cannabis pursuant to the provisions of the ACMPR and the Controlled Drugs and Substances Act (Canada).

Committed to becoming the global leader in delivering organic cannabis solutions that enhance people’s lives, TGOD consistently adheres to the highest levels of excellence. Its world-class management team includes a proven group of leaders with outstanding executive and operational experience specific to consumer packaged goods, consumer products, cannabis and finance industries.

TGOD is positioned as one of the highest quality and most cost efficient cannabis producers in Canada by leveraging innovative technology and low-cost power solutions. It holds one of the largest land packages under a single ACMPR license in Canada, providing future cannabis Agri-park style development and opportunities for joint ventures, licensing and distribution partners. Its industry leading alliance partners include Eaton, Ledcor Group and Hamilton Utilities Corp.

Eaton is the second largest power management company in the world and promises to supply innovative and cost effective power solutions to meet TGOD’s growing demands. Construction management is supplied by Ledcor, Canada’s second largest multidisciplinary construction company and a pioneer in the Green Building Industry. An alliance with Hamilton Utilities Corp allows TGOD to reduce its power costs from $0.13 per kWh to less than $0.05 per kWh. Greenhouse design is provided by Larssen Greenhouse, whose 25-plus years of experience in building some of the most modern and sophisticated greenhouses in the industry will provide TGOD with state of the art, climate-controlled hybrid greenhouse solutions.

Canada is quickly becoming a hub for cannabis investors with over $1.3 billion raised by Canadian companies to date. There are 58 licensed producers to service a population of 36 million and only two organic producers. TGOD, which holds licenses in Ontario and Quebec, is strategically located in both provinces that together claim 22 million Canadians as residents. Another estimated 57 million people live next door in six U.S. bordering states.

The Canadian cannabis market currently has a massive supply demand gap, which makes TGOD’s expansion plans even more important to investors. These plans include a combined build-out capacity of 970,000 square feet, allowing TGOD to produce 116,000 kg annually of organic cannabis. Upon completion, Phase One in Hamilton, Ontario, which is fully funded, will provide 150,000 square feet of growing capacity capable of producing up to 14,000 kg of cannabis or $112 million in revenue at $8 a gram.

The company’s Quebec expansion will be constructed on a recently secured 75-acre property near Montreal. This new property has a planned expansion of 820,000 square feet capable of producing 102,000 kg of organic cannabis. The first phase of this expansion is underway and construction is expected to be completed by the end of 2018. Quebec’s first phase will consist of 220,000 square feet capable of producing 22,000 kg of cannabis. Two additional expansion phases will add 250,000 square feet (26,000 kg of cannabis) and 350,000 square feet (54,000 kg of cannabis). Power costs remain exceptionally low for both facilities with access to all other needed utilities available and close by.

TGOD also plans to gain a share of the burgeoning cannabis oils market which by Q1 2017 accounted for 49 percent of all cannabis sold in Canada under the ACMPR, up from only 27% in Q2 2016. TGOD has ordered a purpose-built extraction laboratory with an estimated commission in Q4 of 2017. This is a commercial-scale CO2 extraction unit capable of processing up to 12,000 kg of raw material per year and producing approximately $170 million worth of organic cannabis oils. Raw cannabis oil provides a significant downstream manufacturing opportunity into several potential recreational market verticals including edibles, beverages, topicals and concentrates.

Data from the Canadian ACMPR Market Trends report indicates a rising number of consumers will continue to seek out healthier, less conspicuous ways to consume cannabis, ensuring sales of organic cannabis oil products remain brisk. Organic cannabis products demand a significant premium compared to non-organic products and the demand keeps growing.

Plans to take the company public are underway with an initial public offering (IPO) slated for January 2018. In November, the company raised $13 million in equity financing and in March closed a $27 million non-brokered private placement. Another $20 million is currently being raised before the IPO in January, which will be utilized for expansion plans.

TGOD is uniquely positioned between the medical and recreational cannabis industry since Canada is scheduled to legalize cannabis for all adults in mid-2018. As of August 2017, TGOD has 2,400 shareholders. Established in 2012, TGOD’s motto, “Making Life Better,” can be seen in its strategic partnerships, top quality management team, and dedication to organic farming and principles.

To learn more about the company and how to invest, contact TGOD directly at financing@tgod.ca

The Green Organic Dutchman (OTC: TGODF), closed Friday's trading session at $0.1747, off by 2.9444%, on 662,965 volume with 208 trades. The average volume for the last 3 months is 674,441 and the stock's 52-week low/high is $0.150000005/$0.935100018.

Recent News

Sanwire Corp. (SNWR)

The QualityStocks Daily Newsletter would like to spotlight Sanwire Corp. (SNWR).

Sanwire Corp. (SNWR) is a diversified company currently focused on technologies for the music industry. The company specializes in locating unique opportunities in fragmented markets and implementing its aggregated technologies to consolidate distinct services into unified platforms of delivery. Sanwire is currently focusing these efforts on advanced entertainment technologies.

Founded in 1997 and based out of Las Vegas, Nevada, Sanwire has operated and sold several subsidiaries as it has worked in various industry segments, including Sanwire Software Inc., Bullmoose Mines Ltd. and Squeeze Report Inc. Currently, there are two new holdings that were added to the company’s portfolio through two recent acquisitions, including Intercept Music Inc. in March 2020 and the Art is War Record Label in June 2020.

Intercept Music Inc. – Artist-Focused Services

Intercept Music Inc. is an entertainment technology company offering a unique suite of artist-focused services that are specifically designed to meet the needs of recording artists. Intercept’s proprietary online platform is dedicated to helping millions of global independent artists effectively promote their music and distribute it worldwide to hundreds of digital stores and every major streaming platform, including Spotify, Apple Music, Amazon Music, Pandora and Google Music.

With Intercept Music, recording artists have all the tools needed to market, promote and sell their music online and through social media. Comprehensive reporting allows artists to track the fan response to their releases, all the way down to individual music tracks.

There are three foundations of Intercept Music’s product offering:

  • Its music distribution platform that is well augmented via the company’s partnership with InGrooves, a wholly owned subsidiary of Universal Music, which is arguably one of the largest music companies in the world.
  • Its social media system, which is tailored to work the way artists use social media to promote their music and engage with their fans. The scheduling system integrates artists’ profiles across multiple social networking sites (Facebook, Twitter, Instagram and YouTube) to facilitate new audience sampling, fan development and the ability for music to be previewed and purchased.
  • The third is represented by the team of developers that brings a unique combination of deep technical expertise (in products like Skype), a team of well-accomplished executives and what the company calls Brand Ambassadors – senior reps from multiple genres who have helped artists earn over 100 Grammys.

Intercept Music is the confluence of technology and this music expertise.

The company currently markets three plans to its clients, with each offering different distribution and royalty options, as well as various marketing and reporting options. The plans are described below:

  • Intercept Distro is a basic plan for self-service music distribution with royalty collection. Artists keep 100% of the royalties while receiving unlimited releases and full analytics with reporting.
  • Intercept Artist includes all of the benefits of the basic Distro plan with added emphasis on social marketing and distribution for emerging artists. With this plan, artists receive scheduled and ad-hoc posting, social media reporting, reusable content libraries and access to other valuable features.
  • Intercept PLUS is available by invite only and is for established artists looking for a complete suite of marketing, distribution and monetization services. The PLUS plan includes everything available through the Distro and Artist plans, as well as offering a dedicated service representative, a branded online store, on-demand merchandise, additional marketing, YouTube monetization and other pro features.

Intercept PLUS is the flagship plan. Artists of this caliber often do $3-$10k/month in merchandise sales alone, at 50%+ profit. Intercept is responsible for marketing to the fan base through its social media system and shares in the profits generated. The stores are managed by intercept so both top-line revenues and bottom-line profits flow through Intercept.

Intercept Music has partnered with Ingrooves Music Group, the largest online music distribution company in the world, for worldwide distribution to streaming services and leading stores. Completing more than 50 billion transactions weekly across over 150 countries, Ingrooves supplies music to leading streaming music platforms and lists some of the world’s largest and most reputable music labels among its clients. The partnership allows Intercept Music and its clients to reach a much wider audience and start earning revenue as soon as possible by leveraging Ingrooves’ quality control systems and direct relationships with leading music streaming services.

Physical Distribution Options for Intercept Music Clients

In a press release on June 25, 2020, Intercept Music announced that it would be offering artists physical distribution through major retailers such as Amazon, FYE and Walmart (http://nnw.fm/NSrbE). The physical distribution will consist of CDs and vinyl and will serve as a supplement to the online streaming platform access provided by the company to represented artists.

“In the current climate, artists can’t play shows or otherwise engage in public at all, so they’re focusing on all other opportunities to bring in revenue,” Intercept Music President Tod Turner stated in a news release. “Our only priority is to help artists monetize music in every way, and with physical distribution added to the mix, we’re leaving no stone unturned in helping artists to earn money from their creative output.”

Creation of Preferred Stock

On June 29, 2020, Sanwire CEO Christopher Whitcomb announced that the company would be filing certificates of designation with the Nevada Secretary of State for its Series A, B and C preferred stock (http://nnw.fm/svrQt).

Speaking about this designation in a news release, Whitcomb stated, “Our paramount goal is to maintain a balanced approach between future investments and shareholder value while minimizing shareholder dilution. The effective utilization of preferred stock ensures our company can grow with the least amount of shareholder dilution.”

Sanwire is leveraging a multi-dimensional strategy that includes additional acquisitions, attracting investors and enhancing the current balance sheet while minimizing dilution for shareholders. A primary goal of these efforts is to support Intercept’s ongoing operations.

Financial Highlights

For the fiscal quarter ended June 30, 2020, Sanwire announced significant revenue growth related to the acquisitions of Intercept Music and Art is War Records. Since acquiring Intercept Music in March and Art is War Records in June, Sanwire’s revenue has increased by approximately 300% (http://nnw.fm/j0S0j). Sanwire attributes the increase in revenue to Intercept Music’s customer acquisition and the release of its PLUS plan.

For the third quarter, revenue is expected to continue an upward climb, owing largely to physical distribution plans and a rising number of PLUS subscribers. The company’s acquisition of Art is War Records is also expected to fuel this growth.

Management

Christopher M. Whitcomb is the current CEO of Sanwire Corp. and Intercept Music Inc. He is a CPA in the state of California, holding bachelor’s degrees in accounting, corporate finance and business management with a focus on real estate. A seasoned executive, his business ventures are always strongly focused on the development and financing of companies.

Whitcomb worked alongside Ralph Tashjian at SMC Entertainment Inc. and Digital Music Universe. They are currently working together again following Sanwire’s acquisition of Intercept Music, which was founded by Tashjian.

Sanwire Corp. (SNWR), closed Friday's trading session at $0.0106, up 6.00%, on 10,000 volume with 1 trade. The average volume for the last 3 months is 647,593 and the stock's 52-week low/high is $0.003299999/$0.100000001.

Recent News

SRAX Inc. (NASDAQ: SRAX)

The QualityStocks Daily Newsletter would like to spotlight SRAX Inc. (NASDAQ: SRAX).

SRAX Inc.'s (NASDAQ: SRAX) is a digital marketing and consumer data management technology company. SRAX’s technology unlocks data to reveal brands’ core consumers and their characteristics across marketing channels.

Through its BIGtoken platform, SRAX has developed a consumer-managed data marketplace where people can own and earn from their data, thereby providing everyone in the internet ecosystem choice, transparency and compensation.

SRAX’s tools deliver a digital competitive advantage for brands in the CPG, automotive, investor relations, luxury and lifestyle verticals by integrating all aspects of the advertising experience, including verified consumer participation, into one platform.

SRAX Verticals

  • SRAX Core: SRAX Core is a custom digital media management platform that enables brands and agencies to surpass the challenges of omnichannel marketing campaigns. It offers one comprehensive dashboard to manage digital media campaigns, inventory and reporting.
  • SRAX Social: SRAX Social is a free social media management tool that makes it easy for brands, agencies and individuals to grow their digital presence. It offers free and unlimited users, Facebook auto boosting, and a custom analytics dashboard. Its managed services team can also build and execute marketing plans for your unique specific needs.
  • SRAX IR: SRAX IR unlocks stock buyers’ behaviors and trends for issuers of publicly traded companies. The platform provides insights on shareholders and market makers, investor relations management, shareholder outreach tools and data-driven marketing.
  • SRAX Auto: SRAX Auto unlocks auto intenders’ data to create measurable connected experiences on the road to purchase. It offers proprietary auto intender profiles, multi touchpoint communication and custom location-based ads.
  • SRAX Shopper: SRAX Shopper delivers a cross channel, premium digital experience at scale to high value shopper audiences. It offers proprietary shopper profiles, cost per click pricing, and custom text and add to cart ad units.
  • SRAX Lux: Launched in June 2019, the SRAX Lux platform targets and reaches luxury consumers at luxury retail stores, high-end art, music, film, fashion and sports events, across all consumer devices.

BIGtoken

BIGtoken, available for download on the App Store and Google Play, revolutionizes data collection. BIGtoken is a platform that creates a secure and transparent environment for consumers to own and earn from their data. To date, there are 15.9 million BIGtoken registered users worldwide.

The optimization and monetization of data is a multibillion-dollar business. Worldwide spending on big data and business analytics solutions reached $166 billion in 2018 and is projected to surge to $260 billion by 2022. BIGtoken’s consumer vision is committed to delivering choice, transparency and compensation to the individual.

Through BIGtoken, consumers earn rewards when they opt into sharing their data and when that data is purchased. Consumers decide what data is shared, who can buy it and how it’s used, and advertisers reach real, responsive audiences. The benefit of this is two-fold: consumers know how their data is used and advertisers gain verified consumer data for targeting.

Users of the BIGtoken app can officially be paid in cash or gift cards in exchange for giving brands access to their anonymized data, answering questions, checking into locations, recruiting new members, and more. Users can deposit their earnings directly into PayPal accounts or be paid through gift cards from favorite retailers such as Walmart.

SRAX has also partnered with several high-profile, nonprofit associations to provide BIGtoken users the ability to donate their earnings. Partnerships include the American Heart Association, dedicated to fighting heart disease and stroke; HealthCorps, which helps high school students make better choices about health and physical fitness; and the ALS Association, which recently launched its Challenge Me campaign.

International Expansion

BIGtoken is formally launching into several international markets and partnering to foster local support. SRAX recently signed a joint venture with the Yash Birla Group to launch BIGtoken in India. Based in Mumbai, the Yash Birla Group, one of India’s largest conglomerates, has diversified interests in consumer and industrial products.

The partnership will bring BIGtoken’s platform to India, which has a digital population of 627 million. The India digital advertising market is $3.6 billion and is set to grow at a compound annual growth rate of 32%, making it one of the largest growing digital ad markets in the world.

SRAX Mexico is led by Moe Avitia, who has more than 18 years of experience in business development and building high-tech teams. SRAX Mexico includes a team of 90 employees, including 70 engineers.

BIGtoken Europe is currently evaluating data centers in individual countries for privacy laws.

Leadership

Christopher Miglino is CEO and founder of SRAX. He has spent the past 20 years working in the digital advertising space and has successfully launched and sold two internet companies. Both of these companies were sold to publicly traded companies on the NASDAQ. He has a detailed understanding of how technology interacts with brands.

Kristoffer Nelson is COO of SRAX and a founding member of BIGtoken. With over 15 years of technology and creative business experience, Nelson has been a guest speaker for Loyola Marymount University among other academic institutions, the National Association of Broadcasters, the IAB and numerous other professional and media organizations.

SRAX Inc. (NASDAQ: SRAX), closed Friday's trading session at $2.39, up 3.913%, on 106,014 volume with 320 trades. The average volume for the last 3 months is 139,436 and the stock's 52-week low/high is $1.04999995/$3.35739994.

Recent News

Predictive Oncology (NASDAQ: POAI)

The QualityStocks Daily Newsletter would like to spotlight Predictive Oncology (POAI).

Predictive Oncology (POAI) is a knowledge-driven precision medicine company focused on applying data and artificial intelligence (AI) to personalized medicine and drug discovery. The company applies its smart tumor profiling and AI platform to extensive genomic and biomarker patient data sets to build predictive models of tumor drug response to improve clinical outcomes for the cancer patients of today and tomorrow. The company has several tools that support its mission of bringing precision medicine to the treatment of cancer.

Through its subsidiaries, Predictive Oncology’s portfolio of assets includes the following:

  • A database of clinically validated historical and outcome data from patient tumors
  • An in-house Clinical Laboratory Improvement Amendments (CLIA)-certified lab
  • A “smart” patient-derived tumor profiling platform
  • An in-house bioinformatics artificial intelligence (AI) platform
  • A new computerized approach growing tumors in the lab to rapidly develop patient specific treatment options
  • An FDA-approved fluid collection and disposal system

Using these resources, and in collaboration with key players in the pharmaceutical, diagnostic and biotech industries Predictive Oncology is working to determine the best pathways for more individualized and effective cancer treatment.

Subsidiaries

Predictive Oncology leverages the synergies of its three wholly owned subsidiaries to bring precision medicine to the diagnosis of cancer.

Helomics applies artificial intelligence to its rich data gathered from the company’s trove of more than 150,000 tumors to personalize cancer therapies for patients as well as drive the development of new targeted therapies in collaborations with pharmaceutical companies. This database, the largest of its kind in the world, is comprised of ovarian, head and neck, colon and pancreas tumors. Helomic’s CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based roadmap for therapy.

In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor™ patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary platform (D-CHIP) to provide a tailored solution to its clients’ specific needs.

TumorGenesis is developing a new, rapid approach to growing tumors in the laboratory without the use of rats or mice, allowing for the identification of biomarkers indicative of cancer. This methodology “fools” the tumor into thinking it is still in the body. As a result, the tumor reacts as it naturally would, thereby increasing the accuracy of the biomarker. Once the biomarkers are identified, they can be used in TumorGenesis’ Oncology Capture Technology Platforms which isolate and helps categorize an individual patient’s heterogeneous tumor samples to enable development of patient-specific treatment options.

Skyline Medical’s patented, FDA-cleared STREAMWAY® System is the first true, direct-to-drain fluid disposal system designed specifically for medical applications such as radiology, endoscopy, urology and cystoscopy procedures. The STREAMWAY system is changing the way healthcare facilities collect and dispose of potentially infectious waste fluid by connecting directly to a facility’s plumbing system to automate the collection, measurement and disposal of waste fluids.

The STREAMWAY minimizes human intervention for better safety and improves compliance with Occupational Safety and Health Administration (OSHA) and other regulatory agency safety guidelines. The STREAMWAY eliminates canisters, carts and evacuated bottles, which reduces overhead costs and minimizes environmental impact by helping to eliminate the approximately 50 million potentially disease-infected canisters that go into landfills annually in the United Sates.

Skyline has achieved sales in five of the seven continents through both direct sales and distributor partners.

Competitive Advantage

Precision medicine has become the holy grail of cancer therapeutics. Data driven predictive models of tumors and their responses are critical in both new drug development and individualized patient treatment. The race has begun to model various tumors, which takes 5 to 7 years of clinical evaluation to establish historical and outcome data.

Predictive Oncology enjoys significant competitive advantage. The company already has a vast historical collection of tumors and related data, plus the ability to obtain existing associated outcome data. While others wait for outcome data, Predictive Oncology is in a unique and powerful position, working to deliver the promise of precision medicine to reality. Predictive Oncology already has the clinical data, including how a tumor responded to certain drugs, an in-house bioinformatics AI platform, and only needs to do the tumor sequencing. The significance is underscored by the collaboration with UPMC Magee-Women’s Hospital, designed to reveal which mutations responded to which drug then develop powerful predictive models for future testing and treatment.

Leadership Team

Dr. Carl Schwartz was appointed to Skyline Medical’s board of directors in March 2015 and became interim president and CEO in May 2016. Dr. Schwartz became CEO of Plastics Research Corporation in 1988, leading the company to become the largest manufacturer of structural foam molding products in the U.S. with more than $60 million in revenues and 300 employees by the time he retired in 2001. He holds a bachelor’s degree and DDS degree from the University of Detroit.

CFO Bob Myers has over 30 years of experience in multiple industries focusing on medical device service and manufacturing. He has spent much of his career as a CFO and controller. Myers holds an MBA in Finance from Adelphi University and a BBA in public accounting from Hofstra University.

Gerald Vardzel, President of Helomics, has over 25 years of healthcare executive management experience developing and implementing commercialization strategies and models for technology launches. His Go-To-Market expertise includes equity financing, strategic planning, market intelligence, M&A, and new market development in both start-up and established settings including fortune 500 market leaders. He has developed innovative solutions for both CLIA and FDA regulatory paths defining the delivery chains from discovery to clinical acceptance. Mr. Vardzel also has significant experience designing and implementing sales and marketing programs tailored not only to expand market share, but to empirically assess client satisfaction, strengthen business processes, and maximize profitability. Mr. Vardzel was previously Vice President of Corporate Development and Strategic Initiatives at Global Specimen Solutions. Furthermore, as an executive affiliate to the healthcare industry, he routinely consults for several small-to-mid sized private equity firms advising on, in part, the feasibility of acquisition targets. Mr. Vardzel graduated from the University of Pittsburgh.

Dr. Mark Collins, Chief Information Officer of Helomics, has held multiple executive roles in a variety of discovery, informatics and bioinformatics functions within global pharma, and founded three startup software companies in the machine learning and drug discovery space. In 2001, Dr. Collins worked for Cellomics (now part of Thermo Fisher Scientific), where he played a pivotal role in establishing the High-Content Cell Analysis market, building and commercializing several key informatics and bioinformatics products. After leaving Thermo Fisher, Dr. Collins developed and commercialized informatics solutions for clinical and translational research, specifically in the specimen tracking, omics data management and NGS analysis space, through key roles at BioFortis, Global Specimens Solutions and Genedata. Dr. Collins received his undergraduate degree in Applied Science from the University of Wolverhampton, UK and his Ph.D. in Microbiology from the University of Surrey, UK.

Predictive Oncology (POAI), closed Friday's trading session at $0.86, up 2.7479%, on 765,608 volume with 971 trades. The average volume for the last 3 months is 1,293,430 and the stock's 52-week low/high is $0.730499982/$5.38999986.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.